FUNCTIONALIZED LIPID NANOPARTICLE-BASED KV1.3 mRNA CANCER IMMUNOTHERAPY

Lipid nanoparticles deliver Kvl.3 mRNA to T cells, enhancing channel expression and function, addressing the suppression issue in HNSCC, thereby improving immunotherapy efficacy and reducing tumor burden.

WO2026236459A1PCT designated stage Publication Date: 2026-11-12UNIVERSITY OF CINCINNATI
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/US2026/027057
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2026-02-20
Filing Date
2026-05-07
Publication Date
2026-11-12

AI Technical Summary

Technical Problem

Current immunotherapies for head and neck squamous cell carcinoma (HNSCC) are ineffective due to the suppression of Kvl.3 potassium channels in tumor-infiltrating T cells, which are essential for maintaining membrane potential and Ca2+ influx, leading to reduced cytotoxicity and cytokine production, and no pharmacologic activators are available.

Method used

Development of lipid nanoparticles (LNPs) functionalized with anti-CD5 antibodies to deliver mRNA encoding Kvl.3 (KCNA3) specifically to T cells, enhancing channel expression and function, thereby increasing Ca2+ signaling and effector cytokine secretion.

Benefits of technology

The approach improves antitumor immunity by increasing T cell infiltration and cytotoxicity, reducing tumor burden, and potentially converting anti-PDl-resistant patients into responders, with reduced immune-related adverse events.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure US2026027057_12112026_PF_FP_ABST
    Figure US2026027057_12112026_PF_FP_ABST
Patent Text Reader

Abstract

A composition, and method of treating a subject using the composition, wherein the composition includes (1) a lipid nanoparticle, (2) a nucleic acid comprising a nucleotide sequence encoding a polypeptide of an ion channel, and (3) a targeting moiety disposed on a surface of the lipid nanoparticle, wherein the targeting moiety is configured to bind a surface marker of an immune cell. The composition is configured to deliver the nucleic acid to the immune cell and increase expression or activity of the polypeptide in the immune cell.
Need to check novelty before this filing date? Find Prior Art

Description

FUNCTIONALIZED LIPID NANOPARTICLE-BASED KVL3 MRNA CANCER IMMUNOTHERAPY CROSS-REFERENCE TO RELATED APPLICATIONS

[0001] This application claims priority to, and the benefit of the filing date of, (1 ) U.S. Provisional Patent Application No. 63 / 801,203, filed on May 7, 2025, titled “Functionalized Lipid Nanovesicle-Based Kvl.3 mRNA Cancer Immunotherapy,’’ and (2) U.S. Provisional Patent Application No. 63 / 986,918, filed on February 20, 2026, titled “Functionalized Lipid Nanoparticle-Based Kvl.3 mRNA Cancer Immunotherapy,” the disclosures of which are incorporated by reference herein in their entireties.STATEMENT OF FEDERAL FUNDING[00021 This invention was made with government support under CA277341 awarded by the National Institutes of Health. The government has certain rights in the invention.FIELD OF THE INVENTION

[0003] This invention relates generally to cancer immunotherapies, and particularly to compositions and methods to revive antitumor activity in subjects.BACKGROUND OF THE INVENTION

[0004] This section is intended to introduce the reader to various aspects of art that may be related to various aspects of the present invention, which are described and / or claimed below. This discussion is believed to be helpful in providing the reader with background infomation to facilitate a better understanding of various aspects of the present invention. Accordingly, it should be understood that these statements are to be read in this light, and not as admissions of prior art.

[0005] Head and neck squamous cell carcinoma (HNSCC) is an aggressive cancer with high mortality, particularly in high-risk cases where the 5-year overall survival rate remains below 50%. The debilitating comorbidities associated with the current standard of care - which includes surgery, radiation, and / or chemotherapy - underscore the urgent need for more effective treatment strategies ( 13). Monoclonal antibodies targeting the immune checkpoint receptor programmed cell death 1 (PD1) have been approved as first-line therapy for patients with metastatic or unresectable recurrent HNSCC, and more recently, for resectable locally advanced tumors expressing programmed cell death 1 ligand (PDL1). These therapies have demonstrated promising improvements in outcomes, including durable remissions after discontinuation of therapy (14, 15). Nevertheless, 80-90% of patients either do not respond or ultimately relapse (16), highlighting theneed for novel strategies to enhance immune-mediated anti-tumor responses and improve immunotherapy efficacy.

[0006] The efficacy of immunotherapies relies on effector T lymphocytes and their ability to infiltrate the tumor and kill cancer cells. Ion channels are critical regulators of these effector functions. T cells express ion channels that regulate the Ca2+ signaling necessary for effector functions like cytotoxicity, cytokine release, and chemotaxis (1). Specifically, Kvl.3 and KCa3.1 potassium channels maintain the membrane potential that drives Ca2+ entry through Ca2+ channels; blockade of these channels suppresses T cell function (17-22). Kvl.3 potassium channels regulate the membrane potential necessary for Ca2+ influx through Ca2+ channels; blockade of these channels suppresses cytokine production, proliferation, and cytotoxicity and, vice versa, an increase of this channel activity facilitates anti -tumor effects (FIG. 1).

[0007] In head and neck squamous cell carcinoma (HNSCC), immunotherapy is often ineffective because of the inability of tumor-infiltrating T cells to sustain calcium-dependent cytotoxic effector functions. Kvl .3 potassium channels in T cells are essential for maintaining the membrane potential necessary for Ca2+ influx; however, they are suppressed in the tumor microenvironment, and no pharmacologic Kvl.3 activators are currently available.SUMMARY OF THE INVENTION

[0008] Certain exemplary aspects of the invention are set forth below. It should be understood that these aspects are presented merely to provide the reader with a brief summary of certain forms the invention might take and that these aspects are not intended to limit the scope of the invention. Indeed, the invention may encompass a variety of aspects that may not be explicitly set forth below.

[0009] As described above in the Background section, the efficacy of immunotherapies relies on effector T lymphocytes and their ability to infiltrate the tumor and kill cancer cells. T cells express ion channels that regulate the Ca2+signaling necessary for effector functions like cytotoxicity and cytokine release (1). Certain ion channels, such as Kvl.3 potassium channels, regulate the membrane potential necessary for Ca2+influx through Ca2+channels; and blockade of these channels suppresses cytokine production, proliferation, and cytotoxicity and, vice versa, an increase of channel activity facilitates anti-tumor effects (FIG. 1).

[0010] Further, as noted in the Background, in head and neck squamous cell carcinoma (HNSCC), immunotherapy is often ineffective because of the inability of tumor-infiltrating T cells to sustain calcium-dependent cytotoxic effector functions. In this cancer, ion channels such as Kvl.3 potassium channels in T cells help maintain the membrane potential necessary for Ca2+influx;however, they are suppressed in the tumor microenvironment, and no pharmacologic Kvl.3 activators are currently available.

[0011] The present inventors have shown that Kvl.3 channels contribute to the failure of immune surveillance in cancer and the resistance to immunotherapies. Kvl.3 channels are suppressed in tumor infiltrating T lymphocytes (TILs) of HNSCC patients and contribute to their decreased cytotoxicity and cytokine release (2, 3, 23, 24). The value of Kvl.3 channels as targets for cancer immunotherapy was confirmed by studies showing that treatment of melanoma bearing mice with T cells overexpressing Kvl.3 increased interleukin-2 (IL-2) and interferon y (IFNy) production, reduced tumor burden and prolonged survival (4).

[0012] The present inventors showed that treatment of head and neck squamous cell carcinoma (HNSCC) patients with aPDl prior to surgery induced an increase in Kvl.3 and KCa3.1 (the other potassium channel expressed in human T cells) channel activities with characteristic changes in patients that showed a reduction in tumor (responder patients) (2). The present inventors observed an increase in Kvl.3 and Ca2+fluxing abilities in circulating cytotoxic T cells exclusively in responder patients, while KCa3.1 activity was increased in both responder and non-responder patients. High Kvl.3 activity and Ca2+fluxes indicate that circulating T cells of patients that responded to aPDl are in a more active state than those of non-responders, and therefore more capable to quickly attack and kill cancer cells. Furthermore, the present inventors observed that this effect persisted long after tumor resection indicating that this mechanism may contribute to the long-lasting remission of patients treated with aPDl. Therefore, a therapy that increases ion channels such as Kvl.3 could be highly beneficial alone in combination with standard immunotherapy as it would improve the immune cell function (such as T cell function), and it can convert a patient resistant to aPDl into a responder (FIG. 2).

[0013] As noted, there are currently no pharmacological activators of ion channels, such as Kvl .3. And so, the present inventors developed liposomal mRNA formulations to overexpress Kvl.3 in T cells. Lipid nanoparticles (LNPs) have been used as vehicles to protect the mRNA from degradation and ensuring its efficient delivery into the cells as its negative charge and hydrophilicity prevent passive diffusion across the plasma membrane (5). Furthermore, LNPs can be functionalized to guarantee a longer in vivo stability and targeted delivery. Ensuring such specificity would limit side effects by sparing other cells that rely on Kvl.3 for their function like macrophages, platelets and adipose cells (6, 7). This approach also allows only a temporary upregulation of Kvl .3 limiting the risks that overactive T cells could pose to healthy tissues and thus the development of immune-related adverse events that occur with conventional cancer immunotherapies (8). Kvl.3 in T cells has been implicated in autoimmunity (9, 10). Overexpression of Kvl .3 in T cells will be, by design, transient because mRNA is in the cytoplasmand incapable of genomic integration, intrinsically unstable, and diluted during cell division. Lastly, LNPs are easily modifiable to target other cells and / or deliver other cargos thus permitting therapies specifically tailored to individual patients.

[0014] Further, the present inventors developed lipid nanoparticles (LNPs) functionalized with anti-CD5 antibodies to specifically deliver mRNA encoding Kvl.3 (KCNA3) to T cells, thereby boosting channel expression and function. Treatment of human T cells with KCNA3-LNPs led to increased Kvl.3 channel protein levels and activity, resulting in enhanced Ca2+influx and elevated secretion of effector cytokines (IL-2, IL- 17, TNF-a, and IFN-y) and cytotoxic molecules (Granzyme A, Perforin, Granulysin, and Fas ligand). In a human peripheral blood mononuclear cell-engrafted HNSCC humanized mouse model, peritumoral delivery of KCNA3-LNPs significantly reduced the tumor burden and increased the infiltration of CD8+Granzyme B+cytotoxic T cells within the tumor, indicating improved antitumor immunity. The present inventors’ study demonstrates that in vivo reprogramming of T cells through targeted Kvl.3 enhancement can overcome the immunosuppressive barriers of the tumor microenvironment and enhance immune-mediated tumor clearance in vivo. This novel approach offers a scalable, cost-effective alternative to ex vivo T cell engineering and holds promise as a therapeutic strategy to improve immunotherapy outcomes in IINSCC and potentially other solid tumors characterized by Kvl.3-dependent immune dysfunctions.

[0015] Recently, the present inventors also found that neoadjuvant treatment of HNSCC patients with a PDl-blocking antibody (anti-PDl) prior to surgery increased both KCa3.1 and Kvl.3 channel activity, accompanied by characteristic changes in patients who exhibited tumor response (24). Enhanced Kvl.3 activity and Ca2+flux were observed in circulating cytotoxic T cells exclusively in responder patients, whereas KCa3.1 activity increased in both responders and nonresponders. Elevated Kvl.3 function and Ca2+signaling suggest that circulating T cells in responder patients may be in a more activated state and thus better poised to rapidly attack and kill cancer cells. Notably, these functional gains persisted long after tumor resection, indicating a mechanism that may contribute to the durable remissions observed following anti-PDl therapy (24). These observations support the concept that therapeutically increasing Kvl.3 activity could enhance T cell function, improve responses to standard immunotherapies, and potentially convert anti-PDl -resistant patients into responders. Although no selective activators of Kvl.3 arc currently available, augmenting Kvl.3 expression offers a viable strategy. Indeed, adoptive transfer of Kvl.3-overexpressing T cells increased interleukin-2 (IL-2) and interferon-y (IFN-y) production, reduced tumor burden, and prolonged survival in a melanoma mouse model (25).

[0016] Here, the present inventors developed a strategy to selectively enhance the cytotoxic function and TME resistance of T cells in vivo, without requiring ex vivo genetic editing. Thepresent inventors engineered a liposomal mRNA formulation to drive overexpression of the Kvl .3 channel specifically within T cells. Lipid nanoparticles (LNPs) were used to encapsulate and protect the mRNA, facilitating efficient cellular delivery by overcoming barriers related to the molecule's negative charge and hydrophilicity, which impede passive membrane diffusion (25). To further improve in vivo stability and enable cell-specific targeting, LNPs were functionalized with surface modifications. This specificity helps minimize off-target effects by sparing other cells that rely on Kvl.3 for their function, such as monocytes / macrophages, platelets, and adipose and cancer cells (27-29). This strategy offers several advantages over traditional ex vivo T cell engineering, including reduced cost, simplified logistics, and the ability to transiently enhance Kvl.3 expression. The transient nature of mRNA expression — due to its cytoplasmic localization, inherent instability, and dilution through cell division — limits prolonged activation, thereby reducing the risk of immune-related adverse events commonly associated with conventional cancer immunotherapies (30).

[0017] One aspect of the present invention, then, is directed to a composition including ( 1) a lipid nanoparticle, (2) a nucleic acid comprising a nucleotide sequence encoding a polypeptide of an ion channel, and (3) a targeting moiety disposed on a surface of the lipid nanoparticle, wherein the targeting moiety is configured to bind a surface marker of an immune cell. The composition is configured to deliver the nucleic acid to the immune cell and increase expression or activity of the polypeptide in the immune cell.

[0018] In certain embodiments of this aspect, the nucleic acid is a messenger RNA (mRNA). In certain embodiments, the immune cell is a T cell. In certain embodiments, the channel is an ion channel. In certain embodiments, the ion channel is a potassium channel. In certain embodiments, the potassium channel is chosen from Kvl.3 and KCa3.1. In one particular embodiment, the potassium channel is Kvl.3 and the nucleotide sequence encodes the KCNA3 gene. Additionally, or alternatively, the potassium channel is KCa3.1 and the nucleotide sequence encodes the KCNN4 gene.

[0019] Thus, this aspect of the present invention may provide lipid nanoparticle compositions carrying mRNA encoding Kvl.3, such as KCNA3 mRNA, and methods of using such compositions to increase Kvl.3 expression and / or activity in T cells in vivo.

[0020] Another aspect of the present invention provides methods of increasing antitumor activity of a T cell in a subject by administering to the subject an effective amount of a composition such as those disclosed herein. Thus, in aspects of the present invention, such a composition includes (1) a lipid nanoparticle, (2) a nucleic acid comprising a nucleotide sequence encoding a polypeptide of an ion channel, and (3) a targeting moiety disposed on a surface of the lipid nanoparticle, wherein the targeting moiety is configured to bind a surface marker of an immunecell. The composition is configured to deliver the nucleic acid to the immune cell and increase expression or activity of the polypeptide in the immune cell.

[0021] In certain embodiments, the nucleic acid is a messenger RNA (mRNA). In certain embodiments, the immune cell is a T cell. In certain embodiments, the channel is an ion channel. In certain embodiments, the ion channel is a potassium channel. In certain embodiments, the potassium channel is chosen from Kvl.3 and KCa3.1. In one particular embodiment, the potassium channel is Kvl.3 and the nucleotide sequence encodes the KCNA3 gene. Additionally, or alternatively, the potassium channel is KCa3.1 and the nucleotide sequence encodes the KCNN4 gene.

[0022] Another aspect of the present invention provides methods of in vivo engineering of immune cells by administering a composition carrying a nucleic acid encoding a polypeptide of an ion channel to a subject, such that the nucleic acid is delivered directly to immune cells within the body. For example, one particular embodiment provides a method of in vivo engineering of T cells by administering a lipid nanoparticle carrying mRNA encoding Kvl.3 to a subject, such that the mRNA is delivered directly to T cells within the body. This approach can eliminate or reduce the need for ex vivo cell isolation, manipulation, transfection, expansion, and reinfusion.

[0023] Another aspect of the present invention provides a kit for preparing and / or administering a composition disclosed herein. In some embodiments, the kit comprises: (i) a lipid nanoparticle composition comprising a targeting moiety disposed on a surface of the lipid nanoparticle and configured to bind a surface marker of an immune cell (such as a T cell); and (ii) a nucleic acid (such as mRNA) comprising a nucleotide sequence encoding an ion channel polypeptide (such as Kvl.3 or KCa3.1), wherein the nucleic acid is configured to be loaded into or associated with the lipid nanoparticle composition before administration.BRIEF DESCRIPTION OF THE DRAWINGS

[0010] The objects and advantages of the disclosed invention will be further appreciated in light of the following detailed descriptions and drawings in which:

[0011] FIG. 1 is a schematic showing the role of ion channels in T cell activation. Antigen engagement to the T cell receptor (TCR) activates a signaling cascade that leads to depletion of the endoplasmic reticulum (ER) Ca2+stores. Ca2+decrease in the ER is sensed by STIM1 that activates the pore forming subunit of the CRAG channel (Orail) and Ca2+influx begins. While Ca2+ions flow into the cell K+channels open. Kvl .3, a voltage-dependent K+channel, is activated by membrane depolarization, and KCa3.1, a Ca2+-activated K* channels, is opened by the rise in cytosolic Ca2+. These K+channels provide an efflux of positive ions that maintains the negative membrane potential (Em) necessary for sustained Ca2+influx and, consequently, NF-AT nucleartranslocation. Blocking this process ultimately blocks Ca2+-dependent activation. TRPM7 (transreceptor potential activated channel) does not appear to be involved in this process, but it is important in T cell motility and Mg2+homeostasis. Other channels expressed in T cells are not reported for sake of clarity. PLCy=phospholipase Cy, IP3=inositol 1,4, 5 -triphosphate, IP3R=IP3 receptor; STIMl=stromal interaction molecule 1: CRAG= Ca2+-release activated Ca2+channel; PMCA=plasma membrane Ca2+ATPase.

[0012] FIG. 2 is a schematic showing potential utility of Kvl.3-LNP's in overcoming immune checkpoint inhibitor resistance. Kvl.3 overexpression will increase Ca2+signaling in T cells and, consequently, their effector functions.

[0013] FIG. 3 is a schematic showing mRNA synthesis workflow.

[0014] FIG. 4 is a schematic showing the structure of functionalized Kvl.3-LNPs. KCNA3 = mRNA encoding Kvl.3.

[0015] FIG. 5 is a graph of LNP size.

[0016] FIG. 6 is a graph showing the amount of mRNA encapsulated in the LNPs.

[0017] FIG. 7 includes images where the left side of the figure shows representative images of CD3+ cells acquired by imaging flow cytometry, and the right side of the figure shows PBMCs were treated with Alexa Fluor 488- conjugated LNPs without mRNA (empty LNPs) or no LNPs for 24 h, stained with antibody panel (as shown in Tablel) and read on a BD S8 imaging cytometer. Representative gating to identify various immune cell subsets is shown here. Briefly, out of the total events acquired, the present inventors first gated moninuclear cells, single cells, and live cells. The live cell population was then gated as CD3-BV421+ T cells, CD19-APC-Cy7+ B cells or CD3-CD19- population. The CD3+ T cells were further gated on Alexa Fluor 488+ LNPs to measure the percentage of CD3+ T cells that incorporated LNPs.

[0018] FIG. 8 includes images showing LNPs in CD4+ and CD8+ T cells.

[0019] FIG. 9 includes images showing LNPs in B cells.

[0020] FIG. 10 includes images showing LNPs in monocytes.

[0021] FIG. 11 includes images showing LNPs in NK cells.

[0022] FIG. 12 includes microphotographs demonstrating that EGFP-LNPs and KCNA3-LNPs effectively translate into intracellular EGFP.

[0023] FIG. 13A-13D includes images showing the gating strategy to measure LNPs and Kvl.3 in CD3+ T cells.

[0024] FIG. 14 includes graphs showing Kvl.3 protein abundance in T cells by flow cytometry. (Left) Representative staggered histogram showing Kvl.3 expression in T cell subsets from healthy donor PBMCs treated with KCNA3-LNPs, EGFP-LNPs (control) or LNPs that donot contain any mRNA (Empty-LNPs). (Right) gMFl for Kvl.3 expression in T cells from four HDs treated with either EGFP-LNPs or KCNA3-LNPs.

[0025] FIG. 15 includes graphs showing Kvl.3 currents in CD8+ T cells after LNP treatment. Currents were recorded in whole-cell configuration with a step pulse protocol from -80 mV holding potential to +50 mV, 900 ms duration, every 30 s. Data are the mean ± SD of 12-13 cells from two donors.

[0026] FIG. 16 is a graph showing that KCNA3-LNPs increased IFNy release by CD8+ T cells (n=4 IIDs).

[0027] FIG. 17 is a schematic of HNSCC mouse model and treatment protocol.

[0028] FIG. 18 includes images and graphs showing CD8+ T cell tumor infiltration and activity. (Left) IHC of CD8 (brown) and Granzyme B (GzB, pink) expression in tumors from KCNA3-NPs treated HNSCC mice and untreated controls (No NPs). (Right) Number of CD8+ T cells and % of GzB+ CD8+T cells in control- (n=2) and KCNA3-NPs-treated (n=4) mice, t-test.

[0029] FIG. 19 includes images showing the evaluation of H&E and IHC slides showed areas of tumor resolution in the KCNA3-LNP treated mice. The pathologist’s report for the KCNA3-LNP mice is summarized in the picture.

[0030] FIG. 20 is a graph showing the association of KCNA3 expression with overall survival in TCGA HNSCC. Kaplan-Meier analysis of overall survival was performed on the TCGA HNSCC cohort, stratified by tumor KCNA3 expression. Patients were divided into KCNA3-low (bottom 50%) and KCNA3-high (top 50%) groups. Higher KCNA3 expression was significantly associated with improved overall survival compared to lower expression. Cox proportional hazards analysis revealed a negative coefficient (-0.264), indicating a protective effect of KCNA3 expression on survival (P = 0.000524).

[0031] FIG. 21 A-21D includes schematics and graphs showing the design and characterization of KCNA3-LNPs and EGFP-LNPs. FIG. 13a is a schematic overview illustrates the strategy for generating KCNA3 or EGFP mRNA via in vitro transcription (IVT), followed by the engineering of functionalized lipid nanoparticles (LNPs) for targeted delivery. This process involves synthesizing KCNA3 mRNA (mRNA encoding Kvl.3 channels), encapsulating it within LNPs designed for efficient transport into the desired cell population, and evaluating the efficacy of the delivery system in vitro and in vivo. FIG. 21B is a schematic illustration of the LNP structure used to deliver KCNA3 / EGFP mRNA (KCNA3-LNPs) or EGFP mRNA only (EGFP-LNPs; control). PE-PEG-biotin refers to l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[biotinyl(polyethylene glycol)-2000], FIG. 21C is a schematic representation of the in vitro-transcribed mRNA constructs that encode Kvl.3 protein (the KCNA3 gene) and EGFP. The KCNA3 mRNA includes a 5' cap, 5' untranslated region (UTR), KCNA3 coding sequence, a self-cleaving P2A linker, EGFP coding sequence, 3' UTR, and apoly(A) tail. The EGFP control mRNA contains a 5' cap, 5' UTR, EGFP coding sequence, 3' UTR, and a poly(A) tail. As shown in FIG.21D, encapsulation of KCNA3 and EGFP mRNA within ENPs was assessed using a RiboGreen RNA quantification assay. RiboGreen fluorescence, measured in intact ENP preparations without Triton X-100, represents unencapsulated (free) mRNA, whereas samples treated with Triton X-100 to disrupt ENP membranes report total mRNA (encapsulated + free). Minimal RiboGreen signal was detected in the absence of detergent, while robust fluorescence was observed following Triton X-100 treatment, indicating that mRNA is predominantly encapsulated within ENPs. Data represent typical experiments performed independently in triplicate.

[0032] FIGS. 22A-22D include images and a graph showing selective association of CD5-coated ENPs with T cells. FIG. 22 A shows the experimental protocol for measuring ENP specificity utilized Alexa Fluor 647-labeled ENPs functionalized with an anti-CD5 antibody (CD5-ENPs); isotype control biotin-conjugated mouse IgGl antibody-functionalized LNPs served as controls (IgG-LNPs). PBMCs from HDs were incubated for 24 h with either CD5-ENPs or IgG-LNPs and stained the following day with cell-specific antibodies to identify immune cell subsets, as detailed in the Materials and Methods. ENP association within each immune cell subset was determined by flow cytometry. FIGS. 22B and 22D are representative flow cytometry plots illustrate ENP+populations expressing Alexa Fluor 647 fluorescence, achieved using Alexa Fluor 647 streptavidin (SAV) for LNP functionalization, in live CD3+, CD4+, CD8+T cells, B cells, NK cells, and monocytes from PBMCs incubated for 24 h with CD5-ENPs (FIG. 22B) or IgG-ENPs (FIG. 22D). The gating strategy for these experiments to identify the various immune subsets is outlined in FIG. 33. Percentages represent the proportion of cells within each parent gate. FIG.22C shows quantification of CD5-LNP+cells (measured by Alexa Fluor 647 fluorescence) in immune cell subsets across five HD PBMCs. Bar graphs represent the mean ± SD.

[0033] FIGS. 23A-23C includes images showing the selective delivery of ENP mRNA to T cells. FIG. 23A shows the experimental protocol for measuring the intracellular delivery of Alexa Fluor 647-labeled LNPs, which were functionalized with anti-CD5 antibodies and loaded with either EGFP mRNA (EGFP-LNPs) or mRNA encoding Kvl.3 channels and EGFP (KCNA3-LNPs). PBMCs from HDs were incubated for 48 h with EGFP-LNPs or KCNA3-LNPs, as detailed in the Materials and Methods section, and mRNA internalization was assessed via microscopy (FIG. 23B) or flow cytometry (FIG. 23C). HD PBMCs incubated with empty LNPs and PBMCs not incubated with any LNPs served as controls. FIG. 23B includes representative confocal images of HD PBMCs incubated with KCNA3-LNPs, EGFP-LNPs, Empty LNPs, or no LNPs are shown, demonstrating EGFP expression (green) and LNP localization (red). Scale bar = 100 pm. FIG.23 C are representative flow cytometry histograms from a representative experiment showingEGFP expression in HD PBMCs treated with either EGFP-LNPs or Empty LNPs. The LNP+ population was identified by gating on the CD3+T cell population expressing NP fluorescence (Alexa Fluor 647). The numbers above each gate represent the percentage of cells within the gate. The experiments were conducted on three HD PBMCs.

[0034] FIGS. 24A-24C includes a series of graphs showing increased Kvl.3 expression and activity in T cells by KCNA3-LNPs. PBMCs from HDs were incubated for 48 h with either EGFP-LNPs or KCNA3-LNPs (1.20 x 108particles / ml; 41.67 pg / ml encapsulated mRNA) as detailed in Materials and Methods. The present inventors then measured Kvl.3 abundance (using flow cytometry) and activity (using electrophysiology), alongside CD69 abundance (using flow cytometry), within the CD3+population. PBMCs treated with LNPs without mRNA (empty LNPs) and PBMCs not treated with any LNPs (no LNPs) served as experimental controls. The flow cytometry experimental protocol and gating strategy are outlined in FIG. 34. FIG. 24A (Left) Staggered histograms from a representative experiment showing Kvl.3 expression in CD3+T cell population of PBMCs treated with KCNA3-LNPs, EGFP-LNPs, empty LNPs, or no LNPs. FIG.24A (Right) The average geometric mean fluorescence intensity (gMFI) of surface Kvl.3 expression in CD3+T cells from four HDs treated with KCNA3-LNPs, EGFP-LNPs, empty LNPs, or no LNPs was determined. Significance was assessed using one-way ANOVA (p<0.0001). Post-hoc testing was performed using the Holm-Sidak multiple comparison test. FIG. 24B shows average geometric mean fluorescence intensity (gMFI) of CD69 expression in CD3+T cells from four HDs treated with KCNA3-LNPs, EGFP-LNPs, empty LNPs, or no LNPs. Significance was assessed using one-way ANOVA (p= 0.1233). Post-hoc testing was performed using Tukey’s test. FIG. 24C shows increased Kvl.3 channel activity in CD3+T cells by KCNA3-LNPs. Representative Kvl.3 currents elicited by step pulse depolarization to +40 mV from -80 mV HP in CD3+T cells from the same donor are shown on the left, and peak Kvl.3 currents measured in CD3+T cells treated with KCNA3-LNPs (n=13 cells) and EGFP-LNPs (n=12 cells) from two HDs are shown on the right. Significance was determined using the Mann- Whitney U test. Bar graphs represent the mean ± SD.

[0035] FIGS. 25A-25C include graphs showing enhanced Ca2+response and cytokine production in T cells by KCNA3-LNPs. In FIG. 25A, the left panel shows a representative Ca2+response, reported as a ratio of Indo- 1 fluorescence at 400 and 480 nm, recorded in activated CD3+T cells from HDs treated with either KCNA3-LNPs or EGFP-LNPs (1.20 x 108particles / ml; 41.67 pg / nil encapsulated mRNA) for 48 h. Cells were loaded with the Indo-1 ratiometric dye, and fluorescence was measured by flow cytometry. Initially, Indo-1 loaded cells were exposed to thapsigargin (TG, indicated by an arrow) in 0 mM Ca2+, followed by 2 mM Ca2+, resulting in a rapid Ca2+influx (refer to Materials and Methods). The right panel displays the average foldchange in peak Ca2+levels. The data represent independent experiments conducted on CD3+T cells isolated from n=3 HDs. Significance was assessed using an unpaired t-test. FIG. 25B shows IFN-y production by HD CD8+T cells treated with increasing concentrations of KCNA3-LNPs or EGFP-LNPs (0.6 x 108, 1.20 x 10sand 2.4 x 108particles / ml, and 20.83 pg / ml, 41.67 pg / ml and 83.34 pg / ml encapsulated mRNA). Cells were then activated for 48 h. IFN-y levels were quantified by ELISA and expressed as fold change relative to the average IFN-y concentration in EGFP-LNP-treated controls. Data represent mean ± SD from n = 4 HDs. Statistical significance was determined by one-way ANOVA (P = 0.0002) with Tukey's multiple-comparisons test. FIG.25C shows CD8+T cells from eight HDs were activated for 48 h and treated with KCNA3-LNPs, EGFP-LNPs (1.20 x 10sparticles / ml; 41.67 pg / ml encapsulated mRNA), empty LNPs (1.20 x 10sparticles / ml), or no LNPs. Cytokines and cytotoxicity biomarkers were measured in the supernatants using the Human CD8 / NK LEGENDplex flow cytometry-based multiplex immunoassay. The heatmap illustrates the fold change in analyte concentration in the KCNA3-LNPs, EGFP-LNPs, and empty LNP-treated groups compared to the no LNP-treated group. Data were obtained from eight HDs, with each donor receiving all LNP treatments. Statistical significance was determined using one-way analysis of variance (ANOVA) or Kruskal-Wallis test, where samples did not meet normality. Post hoc testing was conducted using Dunn's test, and * indicates significance between the KCNA3-LNPs and EGFP-LNPs treated groups.

[0036] FIGS. 26A-26D include a schematic and graphs showing tumor burden reduction by KCNA3-LNP treatment in a hu-PBMC-HNSCC xenograft mouse model. FOG. 26A is a schematic representation of the hu-PBMC-HNSCC mouse studies is presented. NSG mice were injected with Cal 27 spheroids, resulting in palpable tumors by day 23 post-injection. Subsequently, the mice were engrafted with HD PBMCs via the tail vein and peritumoral injections; KCNA3-LNPs or control EGFP-LNPs were then administered peritumorally (7.19 x 10sparticles / ml; 100 pl) every 3-4 days. Tumor volume was measured on treatment days until the study endpoint (day 41). FIG.26B includes line graphs illustrating the tumor volumes measured throughout the course of the study in mice injected with KCNA3-LNPs (n=4) and EGFP-LNPs (n=5). Data are presented as mean ± SEM, and statistical significance between groups was determined by Welch’s t-test, indicated by FIG. 26C: At the study endpoint on day 41, tumors were excised, and their volumes were measured as described in the Materials and Methods. The extracted tumor volumes from mice injected with EGFP-LNPs (n=5) and KCNA3-LNPs (n=4) are displayed in a bar graph, with data presented as means ± SD. Statistical significance was assessed using an unpaired t-test. FIG. 26D: Images on the left show spleens dissected from mice injected with EGFP-LNPs (n=5) and KCNA3-LNPs (n=4), with a scale bar of 10 mm. The bar graph on the right illustrates theweights of the dissected spleens from EGFP-LNP and KCNA3-LNP injected mice, with data shown as means ± SD. Statistical significance was determined using an unpaired t-test.

[0037] FIGS. 27A-27F include schematics, images, and graphs showing enhanced intratumoral presence of functionally competent cytotoxic T cells in a hu-PBMC-HNSCC xenograft mouse model by KCNA3-LNPs. FIG. 27A is a schematic representation of the hu-PBMC-HNSCC mouse studies is shown. NSG mice were injected with Cal 27 spheroids, leading to the development of palpable tumors. Subsequently, the mice were engrafted with HD PBMCs via tail vein and peritumoral injections, and then received peritumoral injections of KCNA3-LNPs or control EGFP- (7.19 x 108particles / ml; 100 ml) every 3-4 days. Tumors were excised at the study endpoint and processed for histological analyses. FIG. 27B: Representative hematoxylin and eosin-stained tumor tissue from hu-PBMC-HNSCC mice treated with EGFP-LNPs or KCNA3-LNPs demonstrates increased inflammatory cell abundance within the tumor in the latter. Detailed annotations of these images are provided in FIG. 38. Scale bar = 50 pm. FIG. 27C: Abundance of tumor infiltrating lymphocytes (TILs) in the periphery of the tumors was scored by a board certified pathologist (see Materials and Methods and Table 3 in Example 2, below) in KCNA3-(n= 4) and EGFP-LNPs-treated (n= 5) mice. The bars represent the mean ± SD, and significance was determined by Mann Whitney Test. FIG. 27D: IHC of the tumor tissue stained for CD8 (brown signal) and Granzyme B (red signal) in representative tumor sections from mice treated with KCNA3-LNPs, EGFP-LNPs, and untreated (no LNPs) mice. Scale bar = 50 pm. FIG. 27E: Intratumoral abundance of CD8+T cells in KCNA3-LNPs (n= 4) and EGFP-LNPs-treated (n= 5) mice, calculated as the number of cells divided by the area of the regions of interest (ROIs) within the intratumoral region of the tissues. FIG. 27F: Granzyme B+CD8+T cell abundance in KCNA3-LNPs (n= 4) and EGFP-LNPs-treated (n= 5) mice, normalized for the area of ROIs. For each biopsy, 5 fields (ROIs) were imaged, and significance was determined by unpaired Student’s t-test. The bars represent the mean ± SD, and each symbol represents an individual measurement from the analyzed fields.

[0038] FIG. 28 is a graph showing association of KCNA3 expression with overall survival in TOGA clear cell renal cell carcinoma (ccRCC). Kaplan-Meier analysis of overall survival in the TCGA ccRCC cohort, stratified by KCNA3 expression. Patients were divided into KCNA3-low (bottom 25%) and KCNA3-high (top 75%) groups. Higher KCNA3 expression was significantly associated with improved overall survival compared to lower expression. Cox proportional hazards analysis revealed a negative coefficient (-0.196), indicating a protective effect of KCNA3 expression on survival (P = 0.000402).

[0039] FIG. 29A and 29B include schematics showing the synthesis and antibody labeling of unilamellar lipid vesicles (ULVs). FIG. 29A is a schematic of ULV synthesis is shown: lipids werecombined in round-bottom glass vessels at the ratios specified in the Materials and Methods, and the resulting film was dried under nitrogen. The lipids were then rehydrated in phosphate-buffered saline (PBS; pH 7.4) and shaken at 37° C for 2 h, followed by sonication and extrusion through 100 nm filter membranes to produce ULVs with an approximate diameter of 100 nm. ULV particle size was determined using a Malvern Zetasizer Nano ZS. FIG. 29B: ULV functionalization was achieved by attaching biotinylated anti-CD5 antibodies to PE-PEG-biotin via a streptavidin binding. The lyophilized antibody-coated nanoparticles were reconstituted with mRNA prior to downstream applications. Detailed protocols are provided in Materials and Methods section of Example 2, below.

[0040] FIG. 30 is a graph showing particle size distribution of ULVs. Representative size distributions of ULVs eluted in sterile-filtered PBS were measured using a Malvern Zetasizer Nano ZS. The results indicate a monodisperse peak with a Z-average diameter of 100.2 nm and a polydispersity index (PDI) of 0.197, signifying a narrow size distribution.

[0041] FIG. 31 is a schematic showing the in vitro transcription (IVT) workflow for mRNA production. Schematic overview details the step-by-step IVT process used to generate capped, high-quality mRNA. Initially, IVT plasmids were linearized with BspQI, followed by DNA cleanup using spin columns. Subsequent in vitro transcription with T7 RNA polymerase synthesized mRNA, which was then purified and evaluated for yield and integrity via NanoDrop spectrophotometry and Agilent Bioanalyzer analysis. Following enzymatic capping and 2'-O-methylation, including RNase I treatment, additional cleanup and quality control steps were performed. Finally, the product was purified using a Monarch® Spin RNA Cleanup Kit and quantified using NanoDrop spectrophotometry. Agilent Bioanalyzer analysis and ratios from spectrophotometry confirmed the mRNA’s suitability for downstream applications (see Materials and Methods in Example 2, below, for details).

[0042] FIG. 32 includes a series of graphs showing RNA quality assessment of in vitro-transcribed KCNA3 mRNA. Agilent 2100 Bioanalyzer (Eukaryote Total RNA Nano chips) electropherograms (left) and corresponding virtual gel images (right) were generated for three representative KCNA3 mRNA preparations produced via in vitro transcription. Electropherograms display RNA migration time in seconds (s) on the horizontal x-axis, and fluorescent signal intensity in fluorescence units (FU) on the vertical y-axis. The 18s and 28s ribosomal peaks arc highlighted. All preparations exhibited intact RNA profiles, with RNA Integrity Numbers (RINs ~ 9.8-10), and demonstrated no evidence of degradation, confirming their suitability for downstream uses.

[0043] FIG. 33 includes a series of images showing flow cytometric gating strategy for identifying major peripheral blood immune cell populations. Representative plots illustrate a sequential gating approach: leukocytes were initially selected based on forward and side scatter,followed by the exclusion of doublets and gating on live cells. Live cells were then divided into CD3+T cells and CD3 non-T cells. Within the CD3+population, CD4+and CD8+T cell subsets were distinguished. The CD3 compartment was further subdivided to identify CD19+B cells, CD56+NK cells, and CDI6 CD14+monocytes. The percentages indicated adjacent to each gate represent the proportion of cells within the parent gate. The data are representative of a typical analysis.

[0044] FIGS. 34A-34E include a schematic and images showing flow cytometry analysis of KCNA3-LNP uptake and expression of Kvl.3 and CD69 in human PBMCs. FIG. 34A shows the experimental protocol for assessing intracellular delivery of KCNA3-LNPs into HD PBMCs and subsequent evaluation of extracellular Kvl .3 and CD69 expression [data shown in FIG. 24] . FIGS.34B-34E: Representative flow cytometry plots illustrate the gating strategy and fluorescence signals used to measure cellular uptake and protein expression following treatment with mRNA-loaded Alexa Fluor 647-labeled LNPs. Lymphocytes were first identified based on forward and side scatter properties. The CD3+T-cell population was gated within the live cell population, and LNP uptake was assessed within this population. Extracellular Kvl.3 expression (PE signal) was measured in CD3+cells. The percentage of Kvl.3-positive cells was quantified across the unstained controls, KCNA3-LNPs, EGFP-LNPs, empty LNPs, and no LNP treatment groups. The percentages of Kvl.3-positive cells are indicated above each gate. A similar gating strategy was employed to assess CD69 abundance within the CD3+population. Finally, gMFI was calculated for Kvl.3 and CD69 populations for all experimental groups (FIGS. 24A and B). The data are representative of a typical experiment.

[0045] FIG. 35 is a graph showing IFN-y levels in CD8+T cells treated with LNPs. CD8+T cells from HDs were activated for 48 h and treated with KCNA3-LNPs, EGFP-LNPs (1.20 x IO8particles / ml; 41.67 pg / ml encapsulated mRNA), empty LNPs (1.20 x 108particles / ml), or left untreated (no LNPs). IFN-y concentrations were measured in the media using ELISA. The bars represent the mean ± SD from four HDs. Statistical significance was assessed using one-way ANOVA (p < 0.0001), followed by Tukey’s post-hoc test. No statistically significant differences were observed between no LNPs, empty LNPs, and EGFP-LNPs groups.

[0046] FIG. 36A and FIG. 36B include graphs showing a comparison of tumor volumes in EGFP-LNP and no-LNP treated hu-PBMC-HNSCC mice. FIG. 36A: Tumor volumes were monitored throughout the study in hu-PBMC-HNSCC mice injected peritumorally with EGFP-LNPs (n = 5) and control mice without LNP injection (no LNPs, n = 4). The experimental protocol for these experiments is outlined in FIG. 26A, and Materials and Methods. Data are presented as mean ± SEM. Welch’s t-test was used to evaluate statistical differences between groups. FIG. 36B: At the study endpoint (day 41), tumors were excised and their volumes were measured as describedin the Materials and Methods. Tumor volumes from EGEP-LNP-injected and no LNP mice are shown as mean ± SD. Statistical significance was assessed using an unpaired t-test.

[0047] FIGS. 37A-37C include images and graphs showing weights of the livers, lungs, and kidneys dissected from hu-PBMC-HNSCC mice injected with EGFP-LNPs or KCNA3-LNPs. Images of the livers (FIG. 37A), lungs (FIG. 37B), and kidneys (FIG. 37C) from hu-PBMC-HNSCC mice injected with EGFP-LNPs (n = 5) and KCNA3-LNPs (n = 4) are shown on the left, with a scale bar of 10 mm. The bar graph on the right displays the corresponding weights as mean ± SD. The experimental protocol for these experiments is outlined in FIG. 26A. Statistical significance was assessed using an unpaired t-test.

[0048] FIG. 38 includes images showing histopathological evidence of enhanced inflammatory infiltration and tumor cell death in hu-PBMC-HNSCC tumors treated with KCNA3-LNPs. Representative hematoxylin and eosin (H&E)-stained sections of hu-PBMC-HNSCC tumors comparing treatment with EGFP-LNPs (left) to KCNA3-LNPs (right). Images were captured at a magnification of 40x. These are the same images shown in FIG. 27B, with detailed annotations by a board-certified pathologist indicating the tumor regions, inflammatory cell infiltrates, and apoptotic tumor cells. The area delimited by dashed lines highlights peritumoral regions characterized by a high density of inflammatory cells. Tumors treated with KCNA3-LNPs exhibited more prominent, thick bands of mononuclear inflammation at the tumor-stroma interface and within the immediate adjacent tumor parenchyma compared to the EGFP-LNP-treated controls. Red circles indicate apoptotic or degenerating tumor cells, identified by condensed or fragmented nuclei and cytoplasmic shrinkage, while green triangles denote representative inflammatory cells infiltrating the tumor periphery. These images are representative of multiple fields examined per group.

[0049] FIG. 39A and FIG. 39B include images and a graph showing a comparison of immune cell infiltration in EGFP-LNP-injected hu-PBMC-HNSCC mice and mice that did not receive LNPs. FIG. 39A: Representative H&E-stained tumor tissue from hu-PBMC-HNSCC mice not injected with LNPs (No LNPs) and mice treated with EGFP-LNPs showing no significant differences in peripheral tumor inflammatory response. Images at 40X magnification, Scale bar = 50 pm. FIG. 39B: Peripheral TIL score was assessed by a board-certified pathologist (see Materials and Methods, and Table 3 in Example 2, below) in EGFP-LNPs and No-LNP-treated mice. The bars represent the mean ± SD, and significance was determined by Mann Whitney Test.DETAILED DESCRIPTION OF THE INVENTION

[0050] One or more specific embodiments of the present invention will be described below. In an effort to provide a concise description of these embodiments, all features of an actualimplementation may not be described in the specification. It should be appreciated that in the development of any such actual implementation, as in any engineering or design project, numerous implementation-specific decisions must be made to achieve the developers’ specific goals, such as compliance with system-related and business-related constraints, which may vary from one implementation to another. Moreover, it should be appreciated that such a development effort might be complex and time consuming, but would nevertheless be a routine undertaking of design, fabrication, and manufacture for those of ordinary skill having the benefit of this disclosure.

[0051] Unless otherwise indicated, all numbers expressing quantities, sizes, concentrations, percentages, dimensions, reaction conditions, formulation ratios, or other numerical values used in the specification and claims are to be understood as being modified in all instances by the term “about.” Thus, unless indicated otherwise, the numerical parameters set forth in the present disclosure are approximations that may vary depending upon the desired properties sought to be obtained by a particular embodiment.

[0052] As used herein, the singular forms “a,” “an,” and “the” include plural referents unless the context clearly dictates otherwise. As used herein, the terms “comprising,” “including,” “containing,” and the like are open-ended terms that do not exclude additional, unrecited elements or method steps. Recitation of ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate value falling within the range.

[0053] As described above in the Background and Summary sections, aspects of the present invention are based, at least in part, on the recognition that impaired ion channel function in immune cells (such as Kvl.3 function in T cells) contributes to defective antitumor immunity in the tumor microenvironment. And so, the present inventors have determined that selective delivery of a nucleic acid, such as mRNA encoding a polypeptide of an ion channel to immune cells (such as Kvl.3 to T cells) can restore or enhance immune cell function (e.g., T-cell effector function).

[0054] One aspect of the present invention, then, is directed to a composition including (1) a lipid nanoparticle, (2) a nucleic acid comprising a nucleotide sequence encoding a polypeptide of an ion channel, and (3) a targeting moiety disposed on a surface of the lipid nanoparticle, wherein the targeting moiety is configured to bind a surface marker of an immune cell. The composition is configured to deliver the nucleic acid to the immune cell and increase expression or activity of the polypeptide in the immune cell.

[0055] In certain embodiments of this aspect, the nucleic acid is a messenger RNA (mRNA). In certain embodiments, the immune cell is a T cell. In certain embodiments, the channel is an ion channel. In certain embodiments, the ion channel is a potassium channel. In certain embodiments, the potassium channel is chosen from Kvl.3 and KCa3.1. In one particularembodiment, the potassium channel is Kvl.3 and the nucleotide sequence encodes the KCNA3 gene or a corresponding homologous gene.. Additionally, or alternatively, the potassium channel is KCa3.1 and the nucleotide sequence encodes the KCNN4 gene or a corresponding homologous gene.

[0056] Thus, this aspect of the present invention may provide lipid nanoparticle compositions carrying mRNA encoding Kvl.3, such as KCNA3 mRNA, and methods of using such compositions to increase Kvl.3 expression and / or activity in T cells in vivo.

[0057] As used herein, the term “Kvl.3” refers to the voltage-gated potassium channel Kvl.3 and includes, where appropriate, human Kvl.3.

[0058] As used herein, the term “KCNA3” refers to a nucleic acid sequence encoding Kvl.3, including DNA templates, RNA transcripts, messenger RNA, coding sequences, and variants that encode a Kvl.3 polypeptide retaining channel function.

[0059] As used herein, the term “KCa3.1” refers to the membrane spanning protein KCa3.1 and includes, where appropriate, human KCa3.1.

[0060] As used herein, the term “KCNN4” refers to a nucleic acid sequence encoding KCa3.1, including DNA templates, RNA transcripts, messenger RNA, coding sequences, and variants that encode a Kvl.3 polypeptide retaining channel function.

[0061] As used herein, the term “lipid nanoparticle” or “LNP” refers to a nanoscale lipid-based carrier capable of encapsulating, complexing, protecting, transporting, and / or delivering a nucleic acid. The term includes unilamellar vesicles, liposomes, lipid nanoparticles, lipid nanovesicles, and related structures, whether cationic, ionizable, PEGylated, functionalized, or otherwise modified.

[0062] As used herein, the term “messenger RNA” or “mRNA” refers to a ribonucleic acid molecule capable of being translated in a cell to produce a polypeptide of interest. In some embodiments, the mRNA is in vitro transcribed, capped, optionally methylated, optionally purified, and optionally comprises a 5' untranslated region, a 3' untranslated region, and a poly(A) tail. In certain embodiments, the mRNA is non-replicating and non-integrating.

[0063] As used herein, the term “targeting moiety” refers to any molecule associated with a nanoparticle that promotes preferential binding, uptake, association, or delivery to a selected cell type. Suitable targeting moictics include, without limitation, antibodies, antigen-binding fragments, Fab fragments, F(ab')2 fragments, single-chain variable fragments (scFv), diabodies, nanobodies, ligands, peptides, aptamers, receptor-binding proteins, and combinations thereof.

[0064] As used herein, the term “surface marker” refers to a cell surface molecule expressed on cells and capable of being bound by a targeting moiety. Similarly, the term “T-cell surface marker” refers to a cell surface molecule expressed on T lymphocytes and capable of beingbound by a targeting moiety. In certain embodiments, the I ce 11 surface marker is CD5. In other embodiments, exemplary T-cell surface markers include CD3, CD4, CD8, CD28, and combinations thereof (as nonlimiting examples).

[0065] In certain embodiments, the disclosed compositions enhance one or more T-cell functions relevant to antitumor immunity, including maintenance of membrane potential, Ca2+ influx, cytokine production, cytotoxic molecule release, migration, tumor infiltration, persistence of effector function in the tumor microenvironment, and killing of tumor cells. In some embodiments, the compositions are useful as stand-alone cancer immunotherapies. In other embodiments, the compositions are administered in combination with one or more additional therapies, including immune checkpoint inhibitors.

[0066] In certain embodiments, the invention provides an alternative to ex vivo T-cell engineering by enabling in vivo engineering of T cells through targeted nucleic acid delivery. In some embodiments, this in vivo engineering is transient and non-integrating, thereby reducing risks associated with permanent genomic alteration while still enhancing antitumor function. As used herein, the phrase “transient and non-integrating” refers to expression of a delivered nucleic acid for a limited period of time without permanent integration into the genome of the recipient cell. In some embodiments, transient expression results from cytoplasmic localization of the mRNA, intrinsic instability of RNA, enzymatic degradation, and / or dilution during cell division.

[0067] In certain embodiments, the invention provides a targeted lipid nanoparticle composition comprising: (i) a lipid nanoparticle; (ii) a nucleic acid comprising mRNA encoding a Kvl.3 potassium channel polypeptide; and (iii) a targeting moiety disposed on or associated with a surface of the lipid nanoparticle and configured to bind a T-cell surface marker.

[0068] The lipid nanoparticle can be any lipid-based nanocarrier capable of transporting nucleic acid to a target cell. In some embodiments, the lipid nanoparticle comprises one or more cationic or ionizable lipids, one or more helper lipids, one or more sterols, one or more PEGylated lipids, or combinations thereof. In certain embodiments, the lipid nanoparticle protects the mRNA from degradation prior to cellular delivery and promotes uptake into target cells and / or endosomal escape following internalization.

[0069] In some embodiments, the lipid nanoparticle comprises a cationic or ionizable lipid, a phospholipid, a sterol, and a PEG-containing lipid. In particular embodiments, the cationic lipid comprises l,2-dioleoyl-3-trimethylammonium-propane (DOTAP). In certain embodiments, the phospholipid comprises phosphatidylcholine (PC). In certain embodiments, the sterol comprises cholesterol. In certain embodiments, the PEG-containing lipid comprises PE-PEG-biotin, such as l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[biotinyl(polyethylene glycol)-2000]. In some embodiments, the lipid nanoparticle comprises DOTAP, PC, PE-PEG-biotin, andcholesterol. In certain embodiments, these components are present at an approximately 5 :2: 1 : 1 molar ratio of DOTAP to PC to PE-PEG-biotin to cholesterol.

[0070] The lipid nanoparticle may be prepared by any suitable method known in the art. In certain embodiments, particles are extruded through a membrane, such as a membrane having a desired pore size, to obtain relatively unifomr particles. In certain embodiments, the membrane may have a pore size of approximately 100 nm.

[0071] In some embodiments, the lipid nanoparticle has an average particle diameter of about 50 nm to about 200 nm, about 70 nm to about 150 nm, about 80 nm to about 130 nm, about 90 nm to about 120 nm, or about 105 nm to 120 nm. In certain embodiments, the average particle diameter is approximately 100 nm. In some embodiments, the particles have a polydispersity index of about 0.3 or less, about 0.25 or less, or about 0.2 or less.

[0072] The mRNA can be encapsulated within the lipid nanopaiticle, electrostatically associated with the lipid nanoparticle, adsorbed to the particle, or otherwise associated with the composition in a manner that enables delivery to the target cell. In certain embodiments, the mRNA is combined with a polycation, such as protamine or protamine sulfate, prior to or during association with the lipid nanoparticle.

[0073] In certain embodiments, the nucleic acid comprises mRNA encoding Kvl.3, such as mRNA comprising a coding sequence for a polypeptide encoded by the KCNA3 gene. The mRNA may encode full-length human Kvl.3 or a functional variant thereof. In certain embodiments, the mRNA is optimized for translation in mammalian cells. In some embodiments, the mRNA includes codon optimization, optimized untranslated regions, modified nucleotides, a cap structure, a poly(A) tail, or combinations thereof.

[0074] In other embodiments, the nucleic acid comprises mRNA encoding KCa3.1, such as mRNA comprising a coding sequence for a polypeptide encoded by the KCNN4 gene. The mRNA may encode full-length human KCa3.1 or a functional variant thereof. In certain embodiments, the mRNA is optimized for translation in mammalian cells. In some embodiments, the mRNA includes codon optimization, optimized untranslated regions, modified nucleotides, a cap structure, a poly(A) tail, or combinations thereof.

[0075] In some embodiments, the mRNA is produced by in vitro transcription from a DNA template comprising a suitable promoter, such as a T7 promoter. In certain embodiments, the mRNA is enzymatically capped. In particular embodiments, the mRNA comprises a Cap 1 structure. In some embodiments, the mRNA further comprises a 5' untranslated region, a Kozak sequence, a coding sequence encoding Kvl.3, a 3' untranslated region, and a poly(A) tail. In some embodiments, the mRNA is purified and quality-controlled prior to formulation with the lipid nanoparticle.[0076| In certain embodiments, the mRNA further comprises a second coding sequence encoding a reporter polypeptide, a selectable marker, or another biologically active polypeptide. In some embodiments, the reporter polypeptide comprises enhanced green fluorescent protein (EGFP). In some embodiments, the coding sequence for the ion channel polypeptide (such as Kvl .3 or KCa3.1) and the coding sequence for the reporter are present on a single transcript and separated by a self-cleaving peptide sequence, a ribosomal skipping sequence, or an internal ribosome entry site. In certain embodiments, the self-cleaving peptide sequence comprises a P2A sequence. In such embodiments, translation of the mRNA in a recipient cell yields separate ion channel and reporter polypeptides.

[0077] As noted above, in certain embodiments, the mRNA is configured to provide transient and non-integrating expression of the ion channel polypeptide (such as Kvl.3) in the recipient immune cell. Because mRNA is generally translated in the cytoplasm and is not integrated into the cellular genome, the expression obtained using the disclosed compositions is temporary, thereby permitting a controlled enhancement of T-cell function without permanently modifying the genome of the treated cell.

[0078] In certain embodiments, the composition comprises a targeting moiety that binds a surface marker of an immune cell (such as a T cell) and thereby promotes preferential delivery of the mRNA to immune cells. In some embodiments, the targeting moiety comprises an antibody or antigen-binding fragment. In certain embodiments, the targeting moiety binds CD5. In some embodiments, the targeting moiety comprises a biotinylated anti-CD5 antibody, which may be coupled to a biotin-containing lipid through streptavidin or a related linker system.

[0079] CD5 is expressed on T cells (and some B cell populations) and can be used to direct nanoparticle association with T lymphocytes, including CD3+ T cells, CD4+ T cells, CD8+ T cells, and, in some embodiments, certain CD5+ B-cell populations. In particular embodiments, the use of a CD5-targeting moiety results in preferential uptake or association with T cells relative to non-target cells such as monocytes and natural killer cells. In some embodiments, the targeting moiety increases delivery of the mRNA to cytotoxic T cells within peripheral blood, lymphoid tissue, tumor-adjacent tissue, tumor-draining lymph nodes, or the tumor microenvironment.

[0080] Although CD5 is specifically exemplified in certain embodiments, the invention is not limited thereto. In other embodiments, the targeting moiety can bind other T-cell-associated markers, including CD3, CD4, CD8, CD28, or combinations thereof (as nonlimiting examples). Selection of a particular targeting moiety can be based on the desired T-cell subset, for example.

[0081] Without being bound by theory, increasing Kvl.3 expression and / or activity in T cells can improve the ability of the cells to maintain the membrane potential needed for sustainedcalcium influx. In turn, increased calcium influx can promote T-cell activation programs and effector functions, including cytokine secretion, cytotoxic granule release, target-cell killing, motility, migration, and infiltration into tumor tissue.

[0082] In certain embodiments, administration of the disclosed composition increases one or more of: Kvl.3 protein abundance, Kvl.3 current amplitude, Kvl.3 current density, KCa3.1 protein abundance, KCa3.1 current amplitude, KCa3.1 current density, calcium influx, cytokine secretion, cytotoxic molecule release, tumor infiltration by cytotoxic T cells, or tumor cell killing. In some embodiments, cytokine secretion includes increased production and / or release of one or more of IL-2, IL- 17, TNF-a, and IFN-y. In some embodiments, cytotoxic molecule release includes increased production and / or release of one or more of Granzyme A, Granzyme B, perforin, granulysin, and Fas ligand.

[0083] In some embodiments, the disclosed compositions increase the abundance or functional competence of CD8+ T cells in or around a tumor. In certain embodiments, the disclosed compositions increase Granzyme B -positive CD8+ T cells within the tumor microenvironment. In some embodiments, these effects are associated with reduced tumor burden, increased inflammatory infiltrates, enhanced immune engagement at the tumor interface, and / or evidence of tumor cell apoptosis or resolution.

[0084] In certain embodiments, the invention provides methods of increasing antitumor activity of a T cell in a subject by administering to the subject an effective amount of a composition such as those disclosed herein. Thus, in aspects of the present invention, such a composition includes (1) a lipid nanoparticle, (2) a nucleic acid comprising a nucleotide sequence encoding a polypeptide of an ion channel, and (3) a targeting moiety disposed on a surface of the lipid nanoparticle, wherein the targeting moiety is configured to bind a surface marker of an immune cell. The composition is configured to deliver the nucleic acid to the immune cell and increase expression or activity of the polypeptide in the immune cell.

[0085] In certain embodiments, the nucleic acid is a messenger RNA (mRNA). In certain embodiments, the immune cell is a T cell. In certain embodiments, the channel is an ion channel. In certain embodiments, the ion channel is a potassium channel. In certain embodiments, the potassium channel is chosen from Kvl.3 and KCa3.1. In one particular embodiment, the potassium channel is Kvl.3 and the nucleotide sequence encodes the KCNA3 gene.Additionally, or alternatively, the potassium channel is KCa3.1 and the nucleotide sequence encodes the KCNN4 gene

[0086] In some embodiments, the method delivers mRNA encoding the ion channel (such as Kvl.3 or KCa3.1) to T cells in vivo, thereby increasing expression or activity of Kvl.3 or KCa3.1 in the T cells and enhancing their antitumor function. As used herein, the term“effective amount” refers to an amount sufficient to produce a desired biological, therapeutic, prophylactic, or diagnostic effect, including, for example, increased Kvl.3 or KCa3.1 expression, increased T-cell calcium signaling, increased cytokine secretion, increased cytotoxic function, increased tumor infiltration by T cells, or reduced tumor burden.

[0087] In some embodiments, the subject to be administered a composition as described herein has cancer. In certain embodiments, the cancer is a solid tumor. In some embodiments, the cancer is head and neck squamous cell carcinoma (HNSCC). In other embodiments, the cancer can be any malignancy in which T-cell dysfunction, suppressed calcium signaling, reduced ion channel activity (such as reduced Kvl.3 or KCa3.1 activity), or an immunosuppressive tumor microenvironment contributes to disease progression or resistance to therapy. Non-limiting examples include renal cell carcinoma, melanoma, lung cancer, breast cancer, ovarian cancer, pancreatic cancer, colorectal cancer, prostate cancer, liver cancer, gastric cancer, glioma, and other solid tumors.

[0088] In some embodiments, administration of the composition reduces tumor burden, slows tumor growth, enhances intratumoral T-cell infiltration, increases the presence of cytotoxic T cells within the tumor, increases the frequency or abundance of Granzyme B-positive CD8+ T cells, improves responsiveness to immunotherapy, or prolongs survival.

[0089] As such, the compositions and methods of the aspects of the present invention can be used to treat various conditions, such as where a subject has cancer, or a solid tumor, or head and neck squamous cell carcinoma (as non-limiting examples of such conditions). As used herein, the terms “treat,” “treating,” and “treatment” refer to alleviating, delaying, reducing, inhibiting, ameliorating, stabilizing, reversing, or preventing one or more signs, symptoms, pathological features, or causes of a disease or condition. In the context of cancer, treatment includes reducing tumor size, slowing tumor growth, enhancing antitumor immunity, increasing sensitivity to immunotherapy, prolonging survival, and / or reducing recurrence.

[0090] In certain embodiments, the compositions described herein are formulated for local administration to a tumor site or a peritumoral region. Local delivery can increase exposure of tumor-associated immune cells and tumor-draining lymphatic structures to the composition while reducing systemic exposure to non-target tissues. In some embodiments, local administration enhances selective in vivo engineering of T cells located in or near the tumor microenvironment.

[0091] In some embodiments, the composition is administered at, within, or adjacent to a tumor site. In certain embodiments, the composition is administered peritumorally, such as by injection into tissue surrounding a tumor mass, at the tumor margin, or in a region within proximate the tumor. In some embodiments, the composition is administered subcutaneouslyadjacent to a tumor. In certain embodiments, the composition is not injected directly into the tumor but rather into tissue near the tumor so as to expose infiltrating immune cells, and other desired cells or structures to the composition.

[0092] In other embodiments, the composition may be administered intratumorally, intranodally, subcutaneously, intradermally, intravenously, intraperitoneally, intramuscularly, or by another suitable route. In particular embodiments, local or peritumoral administration is preferred for tumors accessible by direct injection, including but not limited to head and neck tumors. In some embodiments, repeated local or peritumoral administration is used, such as administration every three to four days, or according to another dosing schedule sufficient to maintain enhancement of the desired ion channel expression in target immune cells.

[0093] In certain embodiments, the compositions and methods disclosed herein are used in combination with one or more immune checkpoint inhibitors. In some embodiments, the checkpoint inhibitor is administered before, concurrently with, or after administration of the targeted lipid nanoparticle composition. In certain embodiments, the checkpoint inhibitor comprises an inhibitor of PD-1 or PD-L1. In some embodiments, the checkpoint inhibitor comprises an anti-PDl antibody. In certain embodiments, the disclosed compositions enhance T-cell responsiveness by increasing ion channel (e.g., Kvl.3 or KCa3.1) expression and restoring calcium-dependent T-cell effector functions.

[0094] In some embodiments, the invention is particularly useful in subjects who are resistant to, or non-responsive to, checkpoint inhibitor therapy. In certain embodiments, administration of the disclosed composition improves the likelihood, magnitude, or durability of response to checkpoint inhibition. In some embodiments, the composition converts a subject from a non-responder to a responder (to such therapy), or from a poorly responsive subject to a more responsive subject, with respect to checkpoint inhibitor therapy.

[0095] In some embodiments, the checkpoint inhibitor and the composition are administered sequentially, simultaneously, or in partially overlapping treatment regimens.

[0096] In addition to checkpoint inhibitors, the disclosed compositions can be combined with any suitable anticancer therapy, including chemotherapy, radiotherapy, surgery, cytokine therapy, oncolytic viruses, cancer vaccines, adoptive cell therapies, bispecific antibodies, targeted small molecules, kinase inhibitors, or other immune modulators.

[0097] In another aspect, the present invention provides methods of in vivo engineering of immune cells by administering a composition carrying a nucleic acid encoding a polypeptide of an ion channel to a subject, such that the nucleic acid is delivered directly to immune cells within the body. For example, one particular embodiment provides a method of in vivo engineering of T cells by administering a lipid nanoparticle carrying mRNA encoding Kvl.3 to a subject, suchthat the mRNA is delivered directly to T cells within the body. This approach can eliminate or reduce the need for ex vivo cell isolation, manipulation, transfection, expansion, and reinfusion.

[0098] In another aspect, the invention provides a kit for preparing and / or administering a composition disclosed herein. In some embodiments, the kit comprises: (i) a lipid nanoparticle composition comprising a targeting moiety disposed on a surface of the lipid nanoparticle and configured to bind a surface marker of an immune cell (such as a T cell); and (ii) a nucleic acid (such as mRNA) comprising a nucleotide sequence encoding an ion channel polypeptide (such as Kvl.3 or KCa3.1), wherein the nucleic acid is configured to be loaded into or associated with the lipid nanoparticle composition before administration.

[0099] In certain embodiments, the lipid nanoparticle component of the kit is provided in lyophilized form. In some embodiments, the nucleic acid component is provided separately from the lipid nanoparticle component and is combined with the lipid nanoparticle shortly before administration.

[0100] In some embodiments, the kit further comprises protamine or protamine sulfate, one or more buffers, one or more reconstitution solutions, one or more sterile containers, syringes, needles, transfer devices, instructions for loading the mRNA into the lipid nanoparticle, instructions for administration, or combinations thereof. In certain embodiments, the kit includes instructions for local or peritumoral administration. In some embodiments, the targeting moiety in the kit comprises an anti-CD5 antibody or antigen-binding fragment thereof.

[0101] In some embodiments, the kit is configured for use in treating cancer, including HNSCC. In certain embodiments, the kit is configured for use alone or in combination with a checkpoint inhibitor regimen.

[0102] In certain embodiments, the disclosed targeted lipid nanoparticle compositions are formulated as pharmaceutical compositions comprising the active nanoparticle formulation and one or more pharmaceutically acceptable carriers, excipients, diluents, stabilizers, buffers, tonicity agents, cryoprotectants, lyoprotectants, preservatives, or combinations thereof.

[0103] In some embodiments, the pharmaceutical composition is formulated as a liquid suspension, injectable preparation, lyophilized cake, reconstitutable powder, sterile dispersion, or other dosage form appropriate for the intended route of administration. In certain embodiments, the pharmaceutical composition is suitable for local, peritumoral, intratumoral, intranodal, intravenous, or subcutaneous administration.

[0104] The amount of nucleic acid, particle concentration, dosing volume, dosing frequency, and treatment duration can vary depending on factors including disease type, tumor burden, route of administration, target tissue accessibility, etc. Those of ordinary skill in the art can determine suitable dosing regimens without undue experimentation in view of the present disclosure.

[0105] Further aspects, explanation, and embodiments of the invention may be taken from the Examples, below.EXAMPLE

[0106] EXAMPLE 1

[0107] Approach:

[0108] The present inventors obtained a Kvl .3 DNA construct in an in vitro transcription (IVT) EGFP plasmid (see 1, “Generation of DNA Constructs,” below). The present inventors used this plasmid to synthesize Kvl.3 mRNA (see 2, “mRNA Synthesis,” below). The present inventors fabricated targeted LNPs (see 3, “Synthesis and functionalization of cationic LNPs,” below) and incorporated the mRNAs into the LNPs (see 4, “mRNA incorporation in the LNPs,” below). The present inventors then demonstrated cell specificity (see 5, “Cell- specificity of LNPs,” below), effective mRNA delivery (see 6, “Intracellular delivery of mRNA,” below), and in vitro and in vivo efficacy (see 7, “KCNA3-LNP efficacy,” below).

[0109] (1) Generation of DNA Constructs'.

[0110] The present inventors obtained two constructs that produce mRNAs encoding (1) Kvl.3 and EGFP, and (2) EGFP (control). EGFP was used for visualization purposes. In construct#!, the Kvl.3 and EGFP are separated by a P2A self-cleaving peptide sequence that induces ribosomal skipping and is commonly used in expression vectors to enable co-expression of multiple proteins from a single mRNA transcript. Therefore, the mRNA generated by this construct translates into separate Kvl.3 and EGFP proteins. These constructs were synthesized through a gene synthesis service (VectorBuilder) in an IVT template plasmid with a T7 promoter, 5’ and 3’ UTR elements and poly(A) tail for mRNA production. Authenticity of plasmid was confirmed by sequencing by VectorBuilder.

[0111] (2) mRNA Synthesis:

[0112] The sequence of events to achieve mRNAs suitable for cell delivery and effective translation through LNPs is summarized in FIG. 3.

[0113] Generating DNA template: The GFP control plasmid and plasmid encoding the Kvl .3 gene were linearized using BSPQI restriction enzyme (New England Biolabs). For each reaction, 1 pg of plasmid DNA was used; the concentration of DNA was determined using the Nanodrop spectrophotometer. The reaction mixture was assembled in a 200 pl nuclease- free microfuge tube or PGR strip tube on ice. The components for a 50 pl reaction included 1 pg of DNA, 5 pl of 10X NEBuffer (IX final concentration), 1 pl of BSPQI restriction enzyme at a concentration of 10U, and nuclease-free water to bring the total volume to 50 pl. The reaction was gently mixed by pipetting up and down and briefly microfuged before incubation in a thermocycler at 50°C for 15minutes, followed by 80°C for 20 minutes and stored at 4°C prior to DNA cleanup. Following the restriction digestion, DNA cleanup was performed using a commercial spin column-based method (Monarch® Spin PCR & DNA Cleanup Kit, New England Biolabs). The digested DNA sample was mixed with 5 volumes of Monarch Buffer BZ and loaded onto a Monarch Spin Column S 1 A. The column was centrifuged, washed twice with Monarch Buffer WZ, and the purified DNA was eluted using 20 pl of nuclease-free water. The concentration and 260 / 280 ratios of the purified template DNA were measured with a Nanodrop spectrophotometer (ThermoFisher). 1 pg of linearized and purified template DNA was used to synthesize mRNA by in vitro transcription (IVT) reaction

[0114] IVT: mRNA synthesis using the HiScribe T7 High Yield RNA Synthesis Kit (New England Biolabs) was conducted as follows. To prevent RNase contamination, gloves were worn, and nuclease-free tubes and reagents were utilized throughout the procedure. Reactions were typically assembled in 20 pl volumes in nuclease-free microfuge tubes or PCR strip tubes. Prior to assembly, all necessary kit components were thawed, mixed, and pulse-spun in a microfuge to collect solutions at the bottom of the tubes. These were then kept on ice. For multiple reactions, a master mix was prepared by combining equal volumes of the 10X reaction buffer and four ribonucleotide (NTP) solutions, using 10 pl per reaction. The reaction was assembled at room temperature in a specific order, combining nuclease-free water, 10X Reaction Buffer, ATP, GTP, UTP, CTP (each at 10 mM final concentration), template DNA (1 pg), DTT (5 mM final), and T7 RNA Polymerase Mix. The mixture was thoroughly mixed and pulse-spun in a microfuge. IVT reaction was carried out at 37°C for 2 hours in a thermocycler. The DNA template was removed by adding 2 pl of DNase I (RNase-free, 2000 units / ml, New England Biolabs) to the newly synthesized mRNA, followed by an incubation at 37°C for 15 min. The concentration and 260 / 280 ratios of the synthesized RNA were measured with a Nanodrop spectrophotometer. Subsequently, the synthesized mRNA was purified using a commercial RNA clean-up kit.

[0115] mRNA cleanup: RNA purification protocol using a column-based method (Monarch RNA Cleanup kit, New England Biolabs) was employed. For samples smaller than 50 pl, the volume was adjusted using nuclease-free water, while for larger samples, the buffer volumes were scaled accordingly. Then, 150 pl of ethanol > 95%) was added to the sample and mixed by gentle pipetting or flicking. The sample was then loaded onto a column inserted into a collection tube and centrifuged for 1 minute. After discarding the flow-through, 500 pl of ash Buffer was added to the column and centrifuged for 1 minute. This wash step was repeated once. The column was then transferred to an RNase-free 1.5 ml microfuge tube, ensuring that the column tip did not contact the flow-through. Finally, the RNA was eluted using nuclease-free water, withthe volume determined based on the specific requirements of downstream applications. The concentration of the eluted RNA and 260 / 280 ratios were measured with a Nanodrop spectrophotometer, and the eluted RNA was either used immediately or stored at - 70°C for future use. Subsequently, a one-step capping reaction was performed on the eluted mRNA.

[0116] mRNA capping: Capping was performed with one-step Cap-1 mRNA synthesis with Vaccinia Capping Enzyme (VCE) and mRNA Cap 2’ -O-methyltransferase (2’-0-me) (New England Biolabs). Purified uncapped mRNA was combined with nuclease-free water to a final volume of 13.5 pl. The mixture was heated at 65°C in a thermocycler for 5 minutes, then placed on ice for 5 minutes. Subsequently, a reaction mixture was prepared by adding the following components in order: 2.0 pl of 10X Capping Buffer, 1.0 pl of 10 mM GTP, 1.0 pl of 4 mM S-adenosyl methionine (SAM), 1.0 pl of Vaccinia Capping Enzyme (10 U / pl), and 1.0 pl of mRNA Cap 2’-O-Methyltransferase (50 U / pl) to the denatured uncapped RNA, bringing the total reaction volume to 20.0 pl. To enhance RNA stability, 0.5 pl of RNase Inhibitor was added to the reaction mixture, with the volume of water adjusted accordingly. The complete reaction mixture was then incubated at 37° C for 60 minutes to facilitate the capping and 2’-O-methylation processes. Following the capping process, the present inventors proceeded with mRNA purification as previously described above. Post-purification, the RNA concentration and 260 / 280 ratios were determined using a Nanodrop spectrophotometer. The quality of the RNA was evaluated with an Agilent 2100 Bioanalyzer (Agilent). The mRNA was either utilized immediately or stored at -80°C for subsequent use.

[0117] (3) Synthesis and functionalization of cationic LNPs

[0118] The LNPs are composed of DOTAP (ll,2-dioleoyl-3-triniethylanimonium-propane chloride salt), an ionizable cationic lipid necessary for RNA encapsulation; 1-a-phosphatidylcholine (PC), a helper lipid to facilitate lysosomal escape; PEGylated and biotinylated l,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[biotinyl(poly ethylene glycol)-2000] (PE-PEG-biotin), for in vivo stability and binding of targeting antibodies; cholesterol, as stabilizer (FIG. 4). Lipids are mixed in a 5:2: 1:1 molar ratio (DOTAP / PC / PE-PEG-biotin / cholesterol), followed by sonication and extrusion with a 100 nm filter. The LNP size, polydispersity index (the width of the particle distribution), potential (the charge of the particle distribution) were measured by dynamic light scattering using a Zctasizcr Nano ZS (Malvern instruments, UK). The average diameter of the LNPs was 109.15 ± 8.87 nm (n=5 independent experiments) (FIG. 5). The concentration of the LNPs was assessed utilizing a NanoSight NS300 (Malvern, UK) microscope. LNP samples, prepared in 100 pl of nuclease-free water, were diluted at a ratio of 1:100 to achieve a particle density of 15 to 50 particles per frame for tracking purposes. Each sample underwent five analyses, each lasting 30 seconds. Across threeindependent experiments, the concentration of the LNPs ranged from 5.48 x 108particles / ml to 8.33 x 108particles / ml, with an average concentration of 7.19 x 108± 1.50 x 10sparticles / ml (mean ± SD, n=3 separate batches of LNPs). LNPs were functionalized with biotinylated antihuman CD5 antibodies. CD5 is expressed in T cells and a subset of B cells (B- la cells) and has been used to deliver modified mRNA encoding CAR (chimeric antigen receptor) to T cells in vivo (11). LNP functionalization was achieved by decorating them with a biotinylated antihuman CD5 primary antibody (10 pg / ml; clone UCHT2, BioLegend) and Alexa Fluor 647-conjugated streptavidin (BioLegend) (12). The functionalized LNPs underwent purification using CL-4B columns (GE Healthcare Bio-Sciences AB), were lyophilized for 48 hours (Labconco), and stored at -80°C for future use.

[0119] (4) mRNA incorporation in the LNPs.

[0120] mRNA (0.25 pg / pl mRNA) was introduced into the LNPs upon rehydration of the lyophilized LNPs in presence of protamine sulfate (MilliporeSigma) at 1:5 M ratio in 100 pl of nuclease-free water. The amount of mRNA incorporated was quantified with the RiboGreen assay (performed as per manufacturer's instructions, ThermoFisher) that detects the free mRNA in the solution. Treatment of LNPs with Triton X-100, a detergent that lyses the LNPs, resulted in an increase in detectable mRNA levels from 0 pg / ml (with intact LNPs) to 278 ± 56 pg / ml following lysis (n= 3 independent experiments, performed in duplicate), showing 100% encapsulation efficiency (FIG. 6).

[0121] This formulation is ideal because it enables the long-term preservation of lyophilized LNPs, ensuring extended shelflife and stability. The mRNA, which is inherently unstable and requires refrigeration, is introduced only al the time of use, minimizing degradation and maintaining potency. This approach enhances the formulation's portability and practicality for clinical and research applications.

[0122] (5) Cell-specificity of LNPs

[0123] Peripheral blood mononuclear cells (PBMCs), isolated from the blood of healthy volunteers, were treated with fluorescent CD5-labeled empty-LNPs (no mRNA) (7.19 x 108LVPs / ml) for 24 hr (no-LNPs, control). 2 X 105cells were treated with 50 pl of reconstituted LNPs (~ 3.6 X 107particles). Cells then underwent flow cytometry and confocal microscopy to measure LNPs binding and incorporation into the targeted cells as previously described. For flow-cytometry, the present inventors labelled cells with antibodies for recognition of different immune cells (Table 1). Samples were run on BD FACSDiscoverTM S8 Cell Sorter: a real time imaging, spectral flow cytometer. LNPs decorated with CD5 antibody were internalized only by T cells (including CD4 and CD8 subsets) (FIGS. 7 and 8) and B cells (FIG. 9), but not in monocytes (FIG. 10) and NK cells (FIG. 11).TABLE 1 - Antibody Cocktail for Cell Specificity Flow Cytometry Experiments Marker Fluorophore Cell TypeZombie UV UV Live / DeadNP Alexa Fluor 488 NPsCD3 BV 421 T cellsCD4 BV 785 Helper T cellsCD8 BV 711 Cytotoxic T cellsCD56 PE Dazzle 594 NK cellCD 16 PE MonocytesCD14 APC MonocyteCD19 APC-CY7 B cells

[0124] (6) Intracellular delivery ofmRNA

[0125] Intracellular delivery of the LNP cargo was determined by confocal microscopy, by flow cytometry (to measure Kvl.3 protein levels) and by electrophysiology (to measure Kvl.3 channel activity) in T cells from healthy donors after exposure to KCNA3-LNPs and EGFP-LNPs (7.19 x 108LVPs / ml). 2 X 105CD3+ T cells or PBMCs were treated with 50 pl of reconstituted LNPs (~ 3.6 X 107particles) for 48 h.

[0126] Confocal microscopy: Treatment of PBMCs from healthy donors with KCNA3- and EGFP-LNPs decorated with Alexa Fluor 647 antibody showed incorporation of fluorescent-labelled LNPs into T cells and the delivery of EGFP-mRNA (FIG. 12).

[0127] Flow-cytometry: The present inventors treated PBMCs with KCNA3-LNPs and EGFP-LNPs and measured Kvl.3 levels in CD3+ T cells. The gating strategy is shown in FIGS.13A-13D. The present inventors found a significant 2.7-fold increase in Kvl.3 proteins in the KCNA3-LNPS group (FIG. 14).

[0128] Electrophysiology: Kvl .3 currents were recorded by whole-cell patch clamp electrophysiology in activated human CD3+ T cells 24 hr after exposure to KCNA3-LNPs and EGFP-LNPs. The present inventors observed significantly higher functional Kvl.3 channels in the KCNA3-LNP group (FIG. 15).

[0129] (7) KCNA3-LNP efficacy

[0130] In vitro: The present inventors measured the amount of IFNy released after 48 hr activation (anti-CD3 / anti-CD28 antibodies) of human CD8+ T cells pre-treated with KCNA3-LNPs, EGFP-LNPs, Empty-LNPs and no-LNPs (7.19 x 108LVPs / ml) by ELISA. The present inventors observed a ~2-fold increase in IFNy in the supernatant only in cells treated with KCNA3-LNPs (FIG. 16).[001311 In vivo: The present inventors tested the efficacy of the KCNA3-LNPs in vivo in a humanized mouse model of HNSCC (FIG. 17). NOD / SCID / IL-2 Receptor Gamma(NSG) mice, which lack the immune system, were flank injected with Cal27 (human HNSCC cell line) spheroids. Once palpable tumor developed, mice were injected peritumorally with PBMCs from healthy donors. KCNA3-LNPs (~ 7.2 X 107particles in 100 pl 1:1 (v:v) solution of PBS and Matrigel) were then injected peritumorally every two days for 14 days (no-LNP control). Thirty-five days after the spheroid injection, tumors were removed and fixed. FFPE sections were then stained for II&E (for histopathology reporting) and II IC (to measure the infiltration of functionally active CD8+GranzymeB+ T cells).

[0132] The present inventors observed an increase in CD8+ T cell number in the tumors in the KCNA3-LNP treated mice (FIG. 18A). A higher number of CD8+ T cells in the tumor of KCNA3-LNP treated mice where functionally active (GranzymeB positive) than in no-LNP mice (FIG. 18B).

[0133] Furthermore, mouse tumors injected with KCNA3-LNPs show areas of tumor resolution (FIG. 19). The pathologist that analyzed these slides reported “increased lymphocyte infiltration at tumor periphery; activated state of lymphocytes; lymphocyte infiltration into tumor and intratumoral stroma and more CD8+ cells compared to controls”. Importantly, there was evidence of tumor apoptosis, especially near immune cell infiltration. Some areas of dead tumor tissue (defined as “tumor resolution”) was observed in 3 out of 4 tumors.

[0134] Overall, KCNA3-LNPs revealed to be a novel cancer therapeutic option for localized administration at the tumor site, enabling targeted engineering of T cells with enhanced efficacy while, possibly, minimizing systemic toxicity and immune-related adverse events.

[0135] EXAMPLE 2

[0136] MATERIALS AND METHODS

[0137] Experimental Design

[0138] This study aimed to assess whether targeted delivery of KCNA3 mRNA (mRNA encoding Kvl.3 channels) via CD5-functionalized lipid nanoparticles (KCNA3-LNPs) could restore Kvl .3 channel function in T cells and enhance antitumor immunity in HNSCC. The experimental design incorporated both in vitro and in vivo methodologies. In vitro investigations utilized human PBMCs from HDs to evaluate nanoparticlc specificity, intracellular mRNA delivery, Kvl.3 protein levels and channel activity, Ca2+signaling, and subsequent cytokine and cytotoxic molecule production. Functional assessments included flow cytometry, electrophysiology, confocal microscopy, ELISA, multiplex cytokine assays, and Ca2+flux measurements. For in vivo therapeutic efficacy evaluation, a humanized HNSCC mouse model was developed by engrafting immunodeficient NSG mice with Cal27 tumor spheroids, followedby the transfer of human PBMCs (hu-PBMC-HNSCC mice). Subsequently, mice received peritumoral injections of either KCNA3-LNPs or control EGFP-LNPs. Treatment effects were determined by evaluating tumor burden, histopathology, immune cell infiltration, and markers of T cell cytotoxicity. Mice were randomly allocated to treatment groups. Sample sizes were determined based on pilot experiments and prior experience with this model, ensuring sufficient statistical power to detect statistically significant differences. No samples were excluded from analysis, and no blinding was performed except for the histopathologic scoring. Statistical analyses are detailed in the “Statistical analysis’’ section, with specific statistical tests and P values provided in the corresponding figures and figure legends.

[0139] TCGA Analysis

[0140] The Cancer Genome Atlas (TCGA) analysis was performed using OncoLnc (www.oncolnc.org), accessed in March 2020. OncoLnc is an interactive tool that assesses correlations between clinical data and expression data of mRNA, miRNAs, and IncRNAs from over 8500 patients across 21 TCGA cancer studies ((57). Specifically, KCNA3 was selected as the gene of interest. A Cox regression analysis was generated for KCNA3 across the 21 cancer types, with a negative Cox coefficient indicating a protective effect against the disease of interest. Subsequently, Kaplan-Meier curves were plotted for KCNA3 in IISNCC (FIG. 20) and ccRCC (FIG. 28). The desired upper and lower quartiles of included patients were selected, and the Kaplan-Meier plots were generated with the n of each percentile group and the Logrank p-value.

[0141] IVT Plasmid Constructs

[0142] Plasmids encoding human KCNA3 (Kvl.3) and EGFP for IVT were custom-designed and cloned by VectorBuilder. All constructs utilized the pmRVacl backbone and incorporated a T7 promoter-driven IVT cassette, an optimized 5' untranslated region (UTR) containing a Kozak sequence, a specified open reading frame (ORF), a human a-globin 3' UTR, and a segmented poly (A) tail (-110 nt) to ensure efficient transcription and mRNA stability. The EGFP control construct encoded only EGFP, while KCNA3 -containing constructs encoded full-length human KCNA3 and EGFP, linked by a self-cleaving peptide (P2A) to facilitate multicistronic expression. All plasmids were propagated in E. coli, sequence-verified by Sanger sequencing, and validated by restriction digestion prior to delivery. Glycerol stocks of verified E. coli clones were provided by VectorBuilder and served as the source material for plasmid preparation and subsequent IVT reactions.

[0143] In vitro transcription and mRNA capping

[0144] Plasmid DNA templates encoding KCNA3 and EGFP or EGFP only (FIG. 21C) were linearized using the BspQI restriction enzyme (New England Biolabs) following themanufacturer’s protocol. Briefly, 1 pg of plasmid DNA was digested and purified using the Monarch PCR & DNA Cleanup Kit (New England Biolabs) following the manufacturer’s protocol. Purified linearized DNA was quantified using a NanoDrop spectrophotometer (Thermo Fisher Scientific). All RNA-related procedures were conducted under RNase-free conditions using nuclease-free reagents, consumables, and work surfaces. IVT reactions were performed according to the manufacturer’s protocol with 1 pg of linearized DNA template and the HiScribe T7 High Yield RNA Synthesis Kit (New England Biolabs), which employs T7 RNA polymerase-mediated transcription to produce mRNA. After IVT, the synthesized mRNA was purified using Monarch® Spin RNA Cleanup Kit (New England Biolabs) according to the manufacturer’s protocol and quantified using NanoDrop spectrophotometry. RNA integrity and size distribution were evaluated using an Agilent 2100 Bioanalyzer (Agilent Technologies). One-step enzymatic capping of IVT mRNA was then performed using Vaccinia capping enzyme (10 U / pL, New England Biolabs) in conjunction with mRNA Cap 2'-O-Methyltransferase (50 U / pL, New England Biolabs) and RNase inhibitor (New England Biolabs), following the manufacturer’s instructions to produce Cap 1-modified mRNA. The capped mRNA was then purified, quantified using NanoDrop spectrophotometry, and its quality was assessed using an Agilent 2100 Bioanalyzer. High-quality RNA was characterized by an RNA Integrity Number (RIN) ranging from 8 to 10, as determined by the bioanalyzer, indicating minimal degradation (FIG. 32). Additional criteria included the presence of distinct 18S and 28S ribosomal peaks on the bioanalyzer electropherograms (FIG. 32), as well as spectrophotometry results showing an A260 / A280 ratio of approximately 2.0 and an A260 / A230 ratio exceeding 1.8. Final capped mRNA preparations were aliquoted to prevent repeated freeze-thaw cycles and stored at -80 °C until needed for downstream LNP formulation and functional studies. The IVT and capping workflows are summarized in FIG. 31.

[0145] Nanoparticles

[0146] LNPs were synthesized and functionalized according to a previously established protocol (79, 55). Briefly, lipid vesicles were prepared by combining chloroform solutions of l,2-dioleoyl-3-trimethylammonium-propane (DOTAP), phosphatidylcholine (PC), phosphatidylethanolamine-polyethylene glycol-biotin (PE-PEG-biotin), and cholesterol (Avanti Polar Lipids Inc.) in a 5:2:1: 1 (DOTAP: PC: PE-PEG-biotin: cholesterol) molar ratio. The mixture was dried under nitrogen gas, rehydrated with phosphate-buffered saline (PBS) at pH 7.4, and subsequently subjected to sonication and extrusion using a LIPEX™ Thermobarrel Extruder (Northern Lipids Inc.) to produce unilamellar vesicles with a diameter of 100 nm. Vesicle size and PDI was verified using a Zetasizer Nano ZS (Malvern Instruments Inc.). The LNPs were then functionalized to specifically target CD5+T cells by conjugating them with abiotinylated anti-human CD5 primary antibody (Clone: UCHT2, 10 pg / mL, Biolegend) and Alexa 647-conjugated streptavidin (SAV, Biolegend). Following purification on CL-4B columns (GE Healthcare Bio-Sciences AB), the LNPs were lyophilized for 48 hours (Labconco) and stored at -80 °C. Subsequently, lyophilized LNPs were reconstituted in 0.25 mg / ml of either KCNA3 mRNA (KCNA3-LNPs) or non-targeting EGFP mRNA (EGFP-LNPs) in conjunction with protamine sulfate (MilliporeSigma) at a 1:5 molar ratio in 100 pl of nuclease-free water. Particle concentration of the resulting formulation was quantified by nanoparticle tracking analysis (NanoSight NS300) and measured 7.19 ± 1.51 x 108particles / ml.

[0147] mRNA encapsulation efficiency measurement

[0148] The EGFP mRNA encapsulation efficiency within LNPs was assessed using the Quant-iT RiboGreen RNA assay kit (ThermoFisher Scientific) following a modified version of the manufacturer's protocol. This fluorescence-based assay relies on the differential accessibility of the RiboGreen dye to mRNA, which fluoresces brightly only when it binds to accessible RNA in solution. LNP samples were prepared in duplicate: one set was treated directly with the RiboGreen reagent to quantify "free" (non-encapsulated) mRNA, while the other set was first treated with 0.5% Triton X-100 detergent to disrupt the LNPs and release all encapsulated mRNA for quantification of "total" mRNA. Fluorescence measurements were conducted using a Biotek Synergy Hl plate reader (excitation 485 nm, emission 528 nm), and concentrations were interpolated from a standard curve generated with known concentrations of unencapsulated mRNA.

[0149] Human Samples and Subjects

[0150] For this study, discarded blood units from the Hoxworth Blood Center at the University of Cincinnati were utilized. Age and demographic data for these units are unavailable. The study protocols and informed consent forms received approval from the University of Cincinnati Institutional Review Board (IRB no. 2013-2516).

[0151] Cell isolation and in vitro activation

[0152] PBMCs were isolated from whole blood using Ficoll Paque density gradient centrifugation (GE Healthcare Biosciences), as previously described (47). CD3+T cells were subsequently isolated from PBMCs via negative selection, utilizing the EasySep Human T cell Enrichment kit (STEMCELL Technologies Inc.), while CD8+T cells were isolated via negative selection from PBMCs using the EasySep Human CD8+T Cell Enrichment Kit (STEMCELL Technologies Inc.) according to the manufacturer’s protocol. Cells were cultured in RPMI 1640 medium (ThermoFisher Scientific) supplemented with 10% human serum (Millipore Sigma), penicillin (200 U / mL), streptomycin (200 pg / mL), 1 mM L-glutamine, and 10 mM HEPES (all from ThermoFisher Scientific) (35).[001531 T cell Activation

[0154] T cells were activated using plate-bound mouse anti-human CD3 and CD28 antibodies, each at a concentration of 10 pg / mL (Biolegend), as previously described (35, 47). Activation times for each experiment are detailed in the individual figure legends.

[0155] In vitro LNP Treatment

[0156] For in vitro experiments, 2 x 105PBMCs or T cells were mixed with 50 pl of KCNA3- or EGFP-LNPs (7.19 x 108particles / ml; input mRNA concentration 0.25 mg / ml) in 250 pl T cell medium (final volume 300 pl) in a 24 well plate, and incubated overnight. This corresponded to 3.60 x 107particles per well, a final particle concentration of 1.20 x 108particles / ml, and approximately 12.5 pg input mRNA per well with a final encapsulated mRNA concentration of 41.67 pg / ml.

[0157] Flow CytometryCell specificity of LNPs functionalized with the anti-CD5 antibody (CD5-LNPs) were determined by measuring their association with immune cell subsets using flow cytometry. Surface staining and immunophenotyping for flow cytometry were conducted following established protocols. Briefly, HD PBMCs (~1 x 106cells per condition) were treated with either Alexa Fluor 647-conjugated CD5-LNPs or IgG-LNPs (LNPs functionalized with IgG isotype control antibody) for 24 h and stained with Zombie Red Live / Dead stain and the following antibodies in Cell Staining buffer (Biolegend) as per the manufacturer’s protocol: Brilliant Violet (BV) 421 -conjugated mouse anti-human CD3, BV 785-conjugated mouse anti-human CD4, BV 711 -conjugated mouse anti -human CD8, APC-CY7- conjugated mouse anti-human CD 19, PE-Dazzle 594-conjugated mouse anti-human CD56, PE-conjugated mouse anti-human CD14. Antibody details, including clone information and RRIDs, are provided in Table 2. After staining, cells were washed, fixed in 4% paraformaldehyde, and resuspended in staining buffer. Data were acquired on a Cytek Northern Lights spectral flow cytometer (Cytek Biosciences). Daily instrument quality control and performance tracking were performed using Cytek Assay Settings beads according to the manufacturer’s instructions. Spectral unmixing was performed using single- stained reference controls and SpectroFlo software (Cytek Biosciences). Forward and side scatter parameters were used to exclude debris, and doublets were excluded by FSC-A versus FSC-H gating. Viable cells were identified using the Zombie Red Live / Dead Stain. LNP population (Alexa Fluor 647+ population) was identified within the various immune cell subsets for both the CD5 and IgG LNPs. Data were analyzed using FlowJo software (BD Biosciences), and gating strategies are illustrated in FIG. 33.TABLE 2 - Antibodies used for Flow Cytometry experimentsMarker Fluorophore Clone Vendor Catalog # RRIDKvl.3 N / A N / A Alomone APC-101-GP AB_2340958 CD19 APC-CY7 HIB19 Biolegend 302218 AB_314248 CD3 BV 421 UCHT1 Biolegend 300434 AB_ 10962690 CD4 BV 785 OKT4 Biolegend 317441 AB_2561365 CD8 BV 711 SKI Biolegend 344734 AB_2565243 CD56 PE Dazzle 594 HCD56 Biolegend 318347 AB_2563563 CD16 PerCP B73.1 Biolegend 360719 AB_2563686 CD 14 PE 3G8 Biolegend 302007 AB_314207 CD69 BV 711 FN50 Biolegend 310943 AB_2566465 CD3 BV 605 OKT3 Biolegend 317321 AB_11126166 Zombie Red N / A N / A Biolegend 423109 N / AZombie UV N / A N / A Biolegend 423107 N / ACD5 Biotin N / A UCHT2 Biolegend 300604 AB_314090 Biotin N / A MOPC21 Biolegend 400103 AB_326427 MouseIgGl, KIsotype Ctrl

[0158] To check for mRNA delivery into the cells, HD PBMCs (~1 x 106cells per condition) were activated in a 96-well tissue culture plate and simultaneously treated for 48 h with Alexa Fluor 647-conjugated EGFP-LNPs or KCNA3-LNPs. Cells treated with LNPs without mRNA (empty-LNPs) and cells not treated with LNPs (no LNPs) served as controls. Cells were then washed with PBS and stained with Zombie UV Live / Dead stain. Cells were washed with cell staining buffer (Biolegend) and fixed with 4% paraformaldehyde for 30 min. Subsequently, cells were stained with surface guinea pig anti-Kvl.3 (Alomone Labs) primary antibody overnight at 4°C. The following day, cells were washed twice in cell staining buffer, followed by a secondary anti-guinea pig (Alexa Fluor 555 goat anti-guinea pig IgG;ThermoFisher) antibody. Cells were then stained with an antibody cocktail consisting of B V 605 conjugated mouse anti-human CD3, and BV 711 conjugated mouse anti-human CD69 antibodies. Complete details of antibodies used in these sets of experiments are presented in Table 2. The present inventors have previously confimred the specificity of the Kvl.3 antibody (39). Data were acquired on a BD Fortessa flow cytometer (BD Biosciences) and analyzed with FlowJo software (BD Biosciences). Compensation was performed using unstained and singlestained PBMCs from HDs, along with UltraComp eBeads (ThermoFisher). EGFP expression,and the abundance of Kvl.3 and CD69, were measured within the CD3+LNP+populations. The gating strategy for these experiments is shown in FIG. 34A.

[0159] Microscopy

[0160] To assess mRNA delivery into the cells, HD PBMCs (~1 x 106cells per condition) were activated in a 96-well tissue culture plate and simultaneously treated for 48 hours with Alexa Fluor 647-conjugated EGFP-LNPs or KCNA3-LNPs. Cells treated with LNPs lacking mRNA (empty LNPs) and those not treated with LNPs (no LNPs) served as controls. After 48 h, cells were visualized for LNP and EGFP fluorescence using a Zeiss 710 laser scanning confocal microscope (Zeiss GmBH) with a 20x lens at room temperature, employing a pinhole setting of 1 airy unit. Data were collected using the microscope's “Multi-Track” option to minimize channel crosstalk, and more than five fields per well were imaged.

[0161] Electrophysiology

[0162] K+currents were recorded using a whole-cell patch clamp configuration with an AxoPatch 200B Amplifier (Molecular Devices). The external solution consisted of (in mM): 150 NaCl, 5 KC1, 2.5 CaCl2, 1 MgCh, and 10 HEPES, pH 7.4. The pipette solution consisted of (in mM): 140 KF, 1 CaCl2, 10 EGTA, 2 MgCh, and 10 HEPES, pH 7.4 (31). The K+current was measured in voltage-clamp mode and induced by step-pulse depolarization to +40 mV from -80 mV holding potential (HP), 800 ms duration, every 30 s. The digitized signals were stored and analyzed using the pClamp 9 software (Molecular Devices).

[0163] Intracellular Ca2+measurement

[0164] Intracellular Ca2+flux was assessed using the Ca2+add-back method, as previously described (31, 39). Briefly, freshly isolated CD8+T cells, treated with KCNA3-LNPs or EGFP-LNPs (1.20 x 108parti cles / ml; 41.67 pg / ml encapsulated mRNA) and activated with anti-CD3 / CD28 antibodies for 48 hours. 1 x 10scells were loaded with the ratiometric Ca2+indicator Indo-1 AM (2 mg / ml, 1:1000 dilution; ThermoFisher) in the presence of 0.015% Pluronic F-127 (ThermoFisher). The cells were incubated in Hank’s Balanced Salt Solution (HBSS) supplemented with 1 mM CaCL. 1 mM MgCL, and 1% FBS (ThermoFisher) for 30 min at 37°C. Following dye loading, the cells were washed three times with HBSS containing 10 mM HEPES (pH 7.0, ThermoFisher) and 1% FBS. Prior to acquisition, the cells were resuspended in Ca2+-frcc HBSS / HEPES buffer containing 0.5 mM EGTA (pH 7.4) and maintained at 37°C. Real-time Indo-1 fluorescence ratios (violet / blue emission) were acquired using a BD LSRFortessa flow cytometer with previously optimized instrument settings. To assess Ca2+influx, cells were first stimulated with thapsigargin (1 pM, MilliporeSigma) in Ca2+-free buffer to deplete intracellular Ca2+stores and activate CRAG channels. This was followed by the addition of 2 mM extracellular Ca2+, allowing Ca2+to enter the cells through the open CRAG channels. Data wereanalyzed using FlowJo software (BD Biosciences), and intracellular Ca2+flux was quantified as the fold change in the Indo-1 fluorescence ratio, calculated by dividing the post- Ca2+addition peak by the baseline fluorescence in Ca2+-free conditions.

[0165] IFN-Y measurements

[0166] HD CD8+T cells were treated with KCNA3- and EGFP-LNPs at final concentrations of 0.6 x 108, 1.20 x 108and 2.4 x 108particles / ml, and 20.83 pg / ml, 41.67 pg / ml and 83.34 pg / ml encapsulated mRNA. Cells were then activated with anti-CD3 / CD28 antibodies for 48 h. In a separate set of experiments, HD CD8+T cells were treated with KCNA3- EGFP- and empty-LNPs at a final LNP concentration of 1.20 x 108particles / ml and encapsulated mRNA concentration of 41.67 pg / ml (CD8+T cells without ENPs served as controls) and activated with anti-CD3 / CD28 antibodies for 48 h. IFN-y levels in cell culture supernatants were measured using a commercially available ELISA kit (ThermoFisher), following the manufacturer’s instructions.

[0167] LEGENDPLEX™ Cytokine and Cytotoxicity Assay

[0168] Cytokine and cytotoxic marker secretion by CD8+T cells was assessed using the LEGENDplex Human CD8 / NK Panel (BioLegend; Cat# 741187), which quantifies IL-17A, IL-2, IL-6, TNF-a, soluble Fas (sFas), soluble Fas ligand (sFasL), IFN-y, Granzyme A, Granzyme B, Perforin, and Granulysin. The assay was performed according to the manufacturer’s instructions. Briefly, 1 x 106CD8+T cells from HDs were activated with anti-CD3 / CD28 antibodies for 72 h in the presence or absence of KCNA3-LNPs or EGFP-LNPs (1.20 x 108particles / ml; 41.67 pg / ml encapsulated mRNA). Supernatants (25 pl) were collected, and the assay was performed in duplicate in a 96-well plate following the manufacturer’s instructions. Samples were acquired on a Cytek Aurora spectral flow cytometer (Cytek Biosciences) equipped with a yellow-green laser and an automated 96-well plate reader using SpectroFlo software (Cytek Biosciences) and manufacturer-recommended settings. Data were analyzed using the LEGENDplex™ Data Analysis Software (Biolegend). Results are reported as a fold change in mean fluorescence intensity (MFI) relative to vehicle-treated controls.

[0169] Cal 27 Cell Culture

[0170] Cal 27 cells, obtained from the American Tissue Culture Collection (ATCC, Manassas, VA, USA), were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum, 1 % penicillin-streptomycin, 1% minimum essential amino acids, 6 mM L-glutamine, and 1% sodium pyruvate, as previously described (all reagents from ThermoFisher) (62). Cell cultures were maintained at 37 °C in a humidified incubator with 5% CO2. Mycoplasma testing was routinely performed using the My-coStrip mycoplasma detection kit (Invivogen, Catalog# rep-mys-50) and yielded negative results for all cultures.[001711 Humanized PBMC-HNSCC xenograft mouse model generation and validation NSG mice were obtained from the Comprehensive Mouse and Cancer Core (Division of Experimental Hematology and Cancer Biology) at Cincinnati Children’s Hospital Medical Center (CCHMC). Six-week-old mice of both sexes were used for the experiments and were flank injected with Cal27 spheroid suspension. To prepare spheroids, Cal27 human oral squamous carcinoma cells were cultured as 3D spheroids using a Matrigel overlay method in which cells were seeded onto Matrigel-coated wells to promote 3D growth, as previously described (63). Briefly, 20,000 cells were seeded into 24-well plates coated with Matrigel (Corning) and maintained in medium containing 1% Matrigel for 4 days. Spheroids were harvested by adding 1 mL of ice-cold Cell Recovery Solution (Corning) per well, incubating at room temperature for 5 minutes, gently pipetting to disrupt the Matrigel, and transferring the plates to 4°C for 20 minutes. Matrix dissolution and spheroid release were confirmed microscopically. All material was collected into 50-mL tubes; wells were rinsed with PBS, and remaining spheroids were recovered by repeating the dissociation steps as needed. The spheroids were pelleted at 300 x g for 5 minutes and pooled.

[0172] To determine the number of cells delivered per mouse, an aliquot of the pooled spheroids was dissociated with TrypLE (ThermoEisher) for 15 min at 37°C. Complete dissociation was confirmed microscopically. Cell counts were consistent across measurements (2.12-2.46 x 105cells / mL; 96-98% viability), and an average concentration of 2 x 105cells / mL was used for dosing calculations. Each mouse received 200 pL of a 1:1 PBS:Matrigel spheroid suspension, corresponding to ~4 x 104Cal27 cells per injection. When the tumors were palpable (23 days post-spheroid injection), each mouse received 10 x 106human PBMCs in 0.5 ml PBS s.c. on the perimeter of the tumor but not inside. Mice were assigned to four groups: Cal27 + PBMCs + KCNA3-LNPs (n = 7); Cal27 + PBMCs + EGFP-LNPs (n = 7); Cal27 + PBMCs + empty LNPs (n = 5); and Cal27 + PBMCs only (n = 2). Mice received 100 pL of their designated LNPs formulation (7.19 x 108particles / ml) per injection, at each time point by s.c. injection within 5 mm proximity to the tumor around the tumor but not inside the tumor. HD PBMCs from a single donor were administered on Day 24 post spheroid injection and LNPs were administered on Days 24, 28, 31, 35, 38, and 40 (FIG. 26A). On Day 41 all animals were euthanized via CO2 inhalation and sacrificed for tumor excision and tissues collection. The length (L), width (W) and height (H) for the tumor was measured using calipers, and tumor volume (V) was calculated using the formula V = x (L x Wx H). Tumor volumes at the time of sacrifice ranged from 21 to 81 mm3across the groups. The study protocol received approval from the Institutional Animal Care and Use Committee (IACUC) of CCHMC (IACUC protocol no. 2021-0032), and University of Cincinnati (protocol no. 21-10-29-01) and all efforts weremade to minimize animal suffering. All mouse experiments were performed in accordance with relevant guidelines and regulations. The study adhered to the Animal Research: Reporting of In Vivo Experiments (ARRIVE) guidelines 2.0, specifically regarding detailed descriptions of animal characteristics, experimental procedures, and statistical methods.

[0173] Immunohistochemistry and histopathologic evaluation

[0174] Excised HNSCC mouse tumors were formalin-fixed, paraffin-embedded (FFPE), and sectioned at a thickness of 5 pm at the Integrated Pathology Research Facility (IPRF) at CCIIMC. Sections were stained following standard II IC protocols. In brief, slides were deparaffinized and stained with monoclonal rabbit anti-human CD8 (clone SP57, Roche) and monoclonal mouse anti-human Granzyme B (Thermo Fisher Scientific, cat# MAI -35461) using a Ventana BenchMark ULTRA automated IHC slide staining system (Roche), as previously described (47, 64). For dual CD8 and Granzyme B staining, primary antibodies were indirectly detected using the ultraView Universal Alkaline Phosphatase Red detection kit (Roche), along with the ultraView Universal DAB Detection Kit (Roche), which includes a horseradish peroxidase multimer and 3,3'-diaminobenzidine tetrahydrochloride (DAB) chromogen. Slides were counterstained with hematoxylin. IHC images were acquired at 20x magnification utilizing a Leica DMi8 microscope equipped with Application Suite X software (Leica Microsystems Inc.). For each slide, five representative fields were selected for imaging. Image analysis was performed using ImageJ software, as previously documented (47, 64). Within each field, a region of interest (ROI) was delineated around the tumor area using the manual drawing tool in Image.!. The CD8+T cells (indicated by the brown signal) within each ROI were quantified, normalized to the ROI area, and expressed as cells per square millimeter. For the dual staining, the present inventors then quantified CD8+T cell signal (brown) with Granzyme B signal (red) in each ROI using Image.!, expressing them as percentage of Granzyme B positive CD8+T cells.

[0175] For histologic evaluation, additional FFPE sections were stained with H&E at the CCHMC IPRF using standard protocols. H&E-stained slides were first reviewed by a board-certified pathologist to assess the overall histopathology across all experimental groups using a light microscope at 40x objective magnification. Digital images were acquired using an Olympus DP23 CMOS camera mounted on an Olympus microscope system. Entire tumor sections were evaluated, and intratumoral lymphocyte infiltration (TIL) was subsequently scored in a separate blinded analysis, in which group allocation was concealed from the pathologist. TIL infiltration was scored semi-quantitatively on a scale of 0-3, where 0 indicates minimal or no infiltration, 1 + indicates mild infiltration, 2+ indicates intermediate infiltration, and 3+ indicates severe infiltration. Histopathologic scores are summarized in Table 3.TABLE 3 - Semiquantitative histopathology analysis of intratumoral lymphocyte infiltration in hu-PBMC-HNSCC miceGroup Peripheral Central Peripheral Central Basophils TILs TILs Neutrophils NeutrophilsKCNA3 #1 illiiiiiiiiiillii iilliiiiiiiiiiiiiiiiiii^ iiiiiliiiiiiiiiiiiiiiiiiiiiiiiiiiiiii^ iiiiiiiiiiii iiiiiiii liiiiiiiiiiii iiiliiiiiiiiiiiiiii iiiliiiiiiiiiiiiiii iiii® ijiiiiiiillliililillili ijiiiiiiiiiiiiiiiii EGFP #1 2+ (focal 3+) 1-2+ 1-2+ 1+ 0-1+ EGFP #2 2+ 1+ 0-1 + 1+ i+ EGFP #3 1-2+ 1+ 1 + 1+ 2+ EGFP #4 1+ (focal 2+) 1+ 1 + 1+ 2+ EGFP #5 1-2+ 1+ 1 + 1+ 2+ iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii iiiiiiii iiiiiiiiiiiiiiiiiiiiiiiii^iii iillliiiiiiiiiiiiiiiiii iilililll liigiiiiiiiii ggg||||||| iiiiiiii illiiiiiiiiiiiiii ilfiiiiiiiiiiiiiiiiii liiiiiiiiiiiii llllilll iiiiiiiiiiii! iiiiiiiiiiiiiiiiiiiiiiiii^iii iiiiiiiiiiiiiiiiiiii No NP No PBMC #1 i+ 0 2+ 0 3+No NP No PBMC #2 i+ 0 2+ 0 3+

[0176] In Table 3, formalin-fixed, paraffin-embedded tumor sections from treatment groups in hu-PBMC-HNSCC humanized mice were stained with hematoxylin and eosin (H&E) using standard protocols. Blinded evaluation was performed by a board-certified pathologist. Immune cell infiltration was scored on a scale of 0 to 3, with 0 indicating minimal or no infiltration, 1 + indicating mild, 2+ indicating intermediate, and 3+ indicating severe infiltration. These scores represent the extent of immune cell presence across the entire tumor sections.

[0177] Statistical Analysis

[0178] Statistical analyses between two groups were performed using Student's t-test (paired or unpaired), the Mann- Whitney U test (when samples did not meet normality assumptions). To perform comparisons between multiple groups, the present inventors performed one way analysis of variance (ANOVA) where samples were normally distributed, or Kruskal- Wallis test, where samples did not meet normality. Post hoc testing following ANOVA or non-parametric tests involved multiple pairwise comparison procedures, utilizing either Holm-Sidak, Tukey, or Dunn’s methods. The normality of sample distributions was assessed using the Shapiro-Wilk test. All statistical tests were conducted using GraphPad Prism 10.6.1 (GraphPad Software LLC,Boston, MA, USA). P value of < 0.05 was considered statistically significant. Specific statistical tests and their corresponding significance values are detailed in the individual figures and figure legends.

[0179] RESULTS

[0180] Association of high Kyl.3 gene (KCNA3) expression with increased survival

[0181] Kaplan-Meier survival analysis of HNSCC patients from The Cancer Genome Atlas (TCGA) cohort demonstrated that elevated expression of the Kvl.3 gene (KCNA3) correlates with improved overall survival (FIG. 20). Patients in the lower 50% of KCNA3 expression exhibited significantly reduced survival compared with those in the upper 50% (Cox coefficient = -0.264; p = 0.000524). A comparable trend was observed in clear cell renal cell carcinoma (ccRCC, FIG. 28), further supporting the relevance of Kvl.3 in cancer. These findings provide a strong rationale for strategies aimed at enhancing Kvl.3 expression in T cells. To this end, the present inventors developed LNPs for the targeted delivery of Kv 1.3 mRNA to T cells, referred to hereafter as KCNA3-LNPs.

[0182] Design and fabrication of KCNA3-LNPs for targeted T cell therapy

[0183] A schematic overview of the general strategy for generating KCNA3-LNPs and testing their efficacy is outlined in FIG. 21A. The KCNA3-LNPs consist of a lipid shell and KCNA3 mRNA, the gene encoding the Kvl.3 potassium channel (FIG. 21B). The LNP shell is comprised of the ionizable cationic lipid l,2-dioleoyl-3-trimethylammonium-propane chloride salt (DOTAP), for RNA encapsulation; La-phosphatidylcholine (PC), to facilitate lysosomal escape; PEGylated and biotinylated l,2-distearoyLsn-glycero-3-phosphoethanolamine-N-[biotinyl(polyethylene glycol)-2000] (PE-PEG-biotin), for in vivo stability (it decreases recognition by the mononuclear phagocytic system and clearance by renal filtration) and binding of targeting antibodies; cholesterol, as stabilizer. The lipids were mixed at a molar ratio of 5:2:1 :1 (DOTAP / PC / PE-PEG-biotin / cholesterol), the solution was then sonicated, and the resulting multilamellar vesicles were extrudes through a 100 nm filter, as previously described (2(5, 31). The process of LNP fabrication is summarized in FIG. 29A. The LNPs were then functionalized with biotinylated anti-CD5 antibodies (isotype matched IgG as control, FIG. 29B). CD5 is expressed by T cells and a subset of B cells and anti-CD5 antibodies have been used to generate Chimeric Antigen Receptor (CAR) T cells in vivo (32-34). Dynamic light scattering using a Zetasizer Nano ZS was employed to measure the LNP size and polydispersity index (PDI). The nanoparticle formulation exhibited a narrow and consistent size distribution (107 ± 12 nm, n=12 preparations) and low PDI (the width of the particle distribution) (0.20 ± 0.05, n=9 preparations), indicating a high degree of sample homogeneity (FIG. 30). An averageparticle concentration of 7.19 ± 1.51 x 108particles / ml was determined for three independent reconstituted LNP formulations by nanoparticle tracking analysis (NT A) with NanoSight NS300.

[0184] The KCNA3-LNPs contained an mRNA encoding both Kvl.3 and EGFP (Enhanced Green Fluorescent Protein), with EGFP serving as a marker for intracellular delivery (FIG. 21C). The DNA template for in vitro transcription (IVT) was engineered to include the coding sequences of KCNA3 and EGFP, separated by a P2A sequence encoding a self-cleaving peptide to enable ribosomal skipping. Translation of this construct results in co-expression of two distinct proteins: Kvl.3 and EGFP. EGFP-only mRNA LNPs (EGFP-LNPs) were used as controls. The DNA constructs were synthesized in an IVT template plasmid containing a T7 promoter, 5' and 3' untranslated regions (UTRs), and a poly(A) tail for mRNA production. The KCNA3 mRNA and control EGFP mRNA were obtained through an IVT reaction followed by capping of the resulting mRNA. The workflow for the IVT reaction and capping is illustrated in FIG. 31 and is detailed in Materials and Methods. Prior to experimental application, the quality of the mRNA obtained after IVT and capping was evaluated (FIG. 32), and only samples meeting the established quality control (QC) criteria (see Materials and Methods) were employed in subsequent assays. This stringent QC guaranteed the integrity and consistency of the mRNA preparations, thereby ensuring that the experimental outcomes reported in the manuscript accurately reflect the effects of high-quality mRNA. The resulting mRNA (0.25 mg / ml) was incorporated into functionalized LNPs by rehydrating lyophilized particles with a solution containing mRNA and protamine, as previously described, and used for downstream experiments (31). mRNA encapsulation efficiency within the LNPs, quantified by the RiboGreen assay, was consistently >95% under these formulation conditions (FIG. 21D).

[0185] Cell specificity and intracellular mRNA delivery of CD5 antibody-functionalized LNPs

[0186] To evaluate cell specificity, the present inventors compared LNPs labeled with biotinylated anti-CD5 antibodies (CD5-LNPs) and those labeled with biotinylated isotype control IgG antibodies (IgG-LNPs). These experiments utilized empty LNPs (LNPs lacking mRNA cargo), which were rendered fluorescent by conjugating them with streptavidin Alexa Fluor 647 antibodies. Peripheral blood mononuclear cells (PBMCs) were isolated from the blood of healthy donors (HDs) and treated with fluorescent CD5-LNPs for 24 h (FIG. 22A) (31). Flow cytometry analysis revealed that CD5-LNPs selectively associated with CD4+ / CD8+T cell subsets, and a small fraction of CD19+B cells, while showing no interaction with CD16‘ CD14+monocytes or CD56+natural killer (NK) cells (FIG. 22B-C) (31, 35, 36). IgG-LNPs did not bind to any of the immune cell subsets (FIG. 22D). The gating strategy used in these experiments is shown in FIG. 33.[001871 To assess intracellular mRNA delivery, the present inventors utilized confocal microscopy and flow cytometry, employing fluorescent EGFP-LNPs labeled with Alexa Fluor 647 (FIG. 23A). Confocal imaging of CD3+T cells from HDs demonstrated EGFP protein expression in PBMCs treated with KCNA3- and EGFP-LNPs, but not in those treated with empty LNPs and no LNPs (FIG. 23B). These findings were conoborated by flow cytometry analysis showing EGFP mRNA delivery by EGFP-LNPs in 87% of CD3+T cells (FIG. 23C).

[0188] Increased functional KvL3 channels in CD3+T Cells following KCNA3-LNP exposure

[0189] Flow cytometry confirmed efficient delivery of mRNA encoding Kvl.3 channels to CD3+T cells by KCNA3-LNPs (FIG. 24A). PBMCs from HDs were treated with fluorescently labeled KCNA3-LNPs, EGFP-LNPs, empty LNPs, or left untreated (no LNPs). Cells (2 x 10’) were treated with LNPs at a final concentration of 1.20 x 108particles / ml and 41.67 pg / ml of encapsulated mRNA for KCNA3- and EGFP-LNPs (see Materials and Methods for calculations). The experimental protocol is shown in FIG. 34A, and flow cytometry gating strategy for these experiments are shown in FIGS. 34B-34E. Kvl.3 protein abundance increased more than twofold in KCNA3-LNP-treated T cells, whereas the geometric mean fluorescence intensity (gMFI) in the EGFP-LNP and empty LNP treated cells was comparable to that of untreated controls (FIG. 24A). This increase in Kvl.3 protein was not accompanied by changes in the early activation marker CD69 (55) (FIG. 24B).

[0190] To determine whether the increase in Kvl.3 protein expression in KCNA3-LNP treated cells corresponded to an increase in functional Kvl.3 channels, the present inventors measured the electrical activity of these channels using patch-clamp electrophysiology (FIG. 24C). Kvl.3 channels open upon membrane depolarization and undergo rapid current decline during sustained depolarization, a process termed C-type inactivation (37). Currents recorded from KCNA3-LNP treated cells displayed the characteristic features of wild-type Kvl.3 channels (FIG. 24C left). Importantly, current amplitude was doubled in KCNA3-LNP treated T cells compared with EGFP-LNP controls (FIG. 24C right). Cell capacitance, a measure of cell size and an indicator of T cell activation (24), was modestly increased in KCNA3-LNP treated cells (2.2 ± 0.2 pF, n=13 cells from two HDs, mean ± SEM) compared with EGFP-LNP treated controls (1.7 ± 0.1 pF, n=12 cells from two HDs; p=0.0261, mean ± SEM). Despite this, Kvl.3 current density remained significantly higher in KCNA3-LNP treated cells (235.8 ± 33 pA / pF) relative to controls (153.5 ± 32.3 pA / pF; p=0.045).

[0191] Enhanced Ca2+signaling and cytokine and cytotoxic molecule release in CD8+T cells by KCNA3-LNPs[00192| An increase in Kvl.3 channels is known to enhance T cell functional capabilities by promoting greater Ca2+influx (77, 18, 38). Flow cytometry experiments using the Ca2+indicator Indo-1 demonstrated that KCNA3-LNPs (1.20 x 108particles / ml; 41.67 pg / ml encapsulated mRNA), induced a 50% increase in Ca2+influx in HD CD8+T cells (FIG. 25 A). Ca2+influx was triggered using thapsigargin (TG) in a Ca2+-free medium, followed by the reintroduction of extracellular Ca2+. TG, an inhibitor of the sarco / endoplasmic reticulum (ER) Ca2+-ATPase (SERCA) pump, depletes the ER Ca2+stores and consequently activates Ca2+-release activated Ca2+(CRAG) channels, allowing Ca2+influx into the cell upon re-introduction of Ca2+in the extracellular milieu. This technique is commonly used to assess the ability of T cells to flux Ca2+through ion channels in a T cell receptor (TCR) -independent manner (24, 31, 39).

[0193] Ca2+influx is one of the earliest events following TCR stimulation and plays a key role in regulating gene expression, including cytokines and exocytosis (33). KCNA3-LNPs led to an increase in IFN-y secretion by activated human CD8+T cells compared to control LNPs (FIG.35), indicating their potential to enhance cytotoxic T cell function. In contrast, treating cells with no LNPs, empty LNPs and EGFP-LNPs did not affect IFN-y release (FIG. 35). The concentration of KCNA3-LNPs used in the Ca2+flux experiments elicited the maximal increase in IFN-y release by T cells (FIG. 25B) and was therefore applied in all subsequent assays. ELISA measurements reflected IFN-y secretion from the entire cell population, including -10% of cells that did not internalize KCNA3-LNPs (FIG. 22B). Consequently, the observed 50% increase in IFN-y likely underestimates the true effect of KCNA3-LNPs on successfully transfected cells.

[0194] Multiplex immunoassay analysis showed that treatment with KCNA3-LNPs (1.20 x 108particles / ml; 41.67 pg / ml encapsulated mRNA), significantly enhanced the release of effector cytokines (IL-2, IL-17, TNF-a, IFN-y), Fas ligand (FasL), and cytotoxic molecules (Granzyme A, perforin, and granulysin) from activated human CD8+T cells (FIG. 25C). These results provide in vitro evidence supporting the antitumor efficacy of KCNA3-LNPs, as the effector molecules upregulated by KCNA3-LNPs are critical for tumor cell killing (34).

[0195] Effective antitumor response following local KCNA3-LNP delivery in tumor-bearing mice

[0196] In vivo experiments were conducted using humanized PBMC (hu-PBMC)-HNSCC xenograft mice to assess the antitumor efficacy of KCNA3-LNPs. Immunodeficient NOD / LtSz-SCID IL-2RG- / - (NSG) mice were flank-injected with tumor spheroids derived from immortalized human Cal27 HNSCC cells (FIG. 26A). Upon tumor formation, PBMCs from a healthy donor were engrafted and, after 24 h, KCNA3- or EGFP-LNPs were injected pcritumorally every 3-4 days (7.19 x 108particles / ml; 100 pl) (FIG. 26A). Tumor development was followed for 17 days post first LNP injection (or for 41 days since spheroid treatment), afterwhich the mice were sacrificed, tumors removed and stained for pathology and T cell function assessments (FIG. 26A).

[0197] Tumor burden was decreased in KCNA3-LNP treated mice as compared to EGFP-LNP treated mice (FIG. 26B) and the volume of the tumors extracted at the end of the experiment (Day 41) was also significantly lower in KCNA3-LNP treated group (FIG. 26C). There was no difference in the tumor volumes between EGFP-LNP mice and mice not injected with LNPs (see FIGS. 36A and 36B). Furthermore, there was a significant increase in the spleen weight in the KCNA3-LNP treated group (FIG. 26D), but not in other organs (FIGS. 37A-37C).

[0198] Next, the present inventors evaluated the impact of KCNA3-LNP treatment on antitumor immunity in vivo in hu-PBMC-HNSCC mice (same treatment as in FIG. 26A).Tumors harvested at the study endpoint were stained for histopathological and immunohistochemical analyses (FIG. 27 A). Hematoxylin and eosin (H&E) staining of formalin-fixed paraffin-embedded (FFPE) tumor sections revealed significant differences in degree of peritumoral inflammatory response. Tumors from KCNA3-LNP-treated mice displayed prominent, thick bands of peritumoral inflammatory infiltrates compared to those from EGFP-LNP-treated controls which more often showed sparse, thin bands of peritumoral inflammation (FIG. 27B and FIG. 38). Immune cell infiltrates showed no differences in EGFP-LNP-injected mice vs mice not injected with LNPs (FIGS. 39A and 39B). Semi-quantitative histopathological scoring (Table 3) further demonstrated that although inflammatory cell infiltrates were detectable across all groups, KCNA3-LNP treatment resulted in a notably higher accumulation of tumorinfiltrating lymphocytes localized to the tumor periphery, consistent with an enhanced immune-engaged TME (FIG. 27 C). Immunohistochemical analysis of tumor sections showed a significant increase in intratumoral CD8+T cell abundance in KCNA3-LNP-treated mice compared to EGFP-LNP -treated controls (FIG. 27D, E). Notably, a substantial proportion of these infiltrating CD8+T cells in the KCNA3-LNP-treated tumors also co-expressed Granzyme B, indicating an enhanced cytotoxic phenotype and functional activation within the tumor (FIG. 27D, F). In contrast, EGFP-LNP-control tumors and tumors from mice not injected with LNPs exhibited fewer CD8+T cells with limited Granzyme B expression, consistent with a less effective antitumor immune response (FIG. 27D-F).

[0199] These data collectively demonstrate that the local delivery of KCNA3-LNPs transforms the tumor immune microenvironment by enhancing the recruitment and cytotoxic CD8+T cells. This process ultimately led to improved tumor-immune engagement and was associated with reduced tumor burden. These findings establish LNP -based KCNA3 mRNA delivery as a powerful strategy to restore antitumor T cell function in an immunosuppressivesolid tumor setting, providing both in vitro and in vivo validation for targeting Kvl.3 potassium channel-dependent immune dysfunction as a potential therapeutic modality for HNSCC.

[0200] DISCUSSION

[0201] Immunotherapies have transformed cancer treatment, but durable responses in solid tumors such as HNSCC remain limited, with most patients not benefiting from conventional immunotherapy alone (76). A major barrier is the immunosuppressive TME, which impairs T cell Ca2+signaling, cytotoxicity, cytokine secretion, and migration (38). Here, targeted delivery of KCNA3 mRNA via LNPs selectively enhances Kvl.3 channel expression in T cells, boosting Ca2+signaling — a critical early step in activation. Consequently, secretion of key cytokines as well as cytotoxic molecules is increased, leading to improved T cell antitumor functions.Localized peritumoral KCNA3-LNP administration in a preclinical HNSCC model reduced tumor burden, restored robust T cell-mediated antitumor immunity, and increased intratumoral Granzyme B+CD8+T cell infiltration, demonstrating that KCNA3-LNPs reprogram the TME toward an antitumor phenotype.

[0202] Kvl.3 potassium channels are critical regulators of T cell survival, proliferation, and effector function, including cytokine production and cytotoxicity, particularly in effector memory T cells (77, 78). Although expressed in Tregs, their contribution to suppressive function is minimal (40). In HNSCC, TME-mediated downregulation of Kvl.3 in cytotoxic T cells limits antitumor immunity and response to anti-PDl therapy (24, 39). Restoring Kvl.3 activity in T cells is therefore critical for re-establishing effective antitumor immunity. In contrast, Kvl.3 is overexpressed in many tumors, including HNSCC, supporting tumor cell proliferation and survival via plasma membrane and mitochondrial functions (29, 41-43). From the perspective of tumor cells, Kvl.3 inhibition is therefore predicted to exert a strong antitumor effect. This opposing role of Kvl.3 underscores the need for precise targeting, as indiscriminate elevation could enhance tumor survival or affect other cell populations expressing Kvl.3, including monocytes and platelets (28, 44). The present inventors’ anti-CD5-functionalized LNPs restrict KCNA3 overexpression predominantly to T cells, minimizing off-target exposure (33, 34). Moreover, transient mRNA expression may limit long-term adverse effects (45, 46).

[0203] The LNP-based, cell-targeted mRNA delivery offers several advantages. The present inventors’ biocompatiblc LNPs enable efficient mRNA cytosolic delivery following cellular uptake. Composed of ionizable lipids, helper lipids, cholesterol, and PEGylated lipids, LNPs protect the cargo from degradation while enhancing cellular uptake and promoting endosomal escape — features that are central to the clinical success of mRNA vaccines and other nucleic acid-based therapeutics (26). The present inventors have previously used a similar LNP platform to deliver oligonucleotides targeting Kvl.3 in effector memory T cells, achieving selectivechannel silencing and therapeutic benefit in a murine lupus nephritis model (47). Building on this experience, the present inventors now repurposed the platform for Kvl.3 augmentation, incorporating CD5 -targeted functionalization to selectively direct mRNA delivery to T lymphocytes. Furthermore, KCNA3-LNPs were engineered to allow unstable mRNA to be loaded into lyophilized LNPs immediately prior to administration, thereby combining the potential for extended shelf life with minimized cargo degradation (31, 48). Particle concentration and mRNA incorporation were quantified in three independent formulations. The consistent observation of functional outcomes across various independent formulations underscores the platform's reproducibility and stability. Pharmacostability studies are necessary to further validate this formulation strategy. Beyond molecular delivery, LNPs offer substantial translational advantages at the therapeutic level. Compared with adoptive T cell transfer, LNP delivery simplifies logistics, reduces cost, improves scalability, and provides transient, non-genetically permanent T cell reprogramming.

[0204] Anti-CD5 antibodies were selected as the cell-targeting moiety. CD5 is a surface glycoprotein expressed on T cells and a subset of B cells (33, 34). In T cells, CD5 negatively regulates TCR signaling, shaping thymic selection, maintaining self-tolerance, and limiting excessive activation (33, 34). This makes CD5 an attractive handle for immune modulation, including engineered T cell and Treg strategies (49-52). Consistent with this biology, CD5-functionalized LNPs preferentially associated with CD3+T cells, with limited uptake by CD19+B cells. While CD5+B cells may contribute to tumor-associated immune regulation, their role in human solid tumors remains unclear (33, 53). However, in hu-PBMC-engrafted mice, B cells are present only at minimal levels and fail to persist over time, resulting in a human leukocyte population predominantly composed of T cells (54-56). Overall, the observed T cell selectivity supports CD5 as a safe and effective targeting handle, and EGFP-LNP controls showed no functional effects attributable to the targeting moiety alone.

[0205] Functionally, KCNA3-LNPs, by augmenting Kvl.3 in T cells, increase Ca2+signaling, enhance the cell cytotoxicity and cytokine secretion. KCNA3-LNP treatment doubled Kvl.3 current amplitude and increased channel protein expression without inducing early activation markers such as CD69, indicating functional potentiation without nonspecific early T cell activation that can drive terminal differentiation (24). Overall, KCNA3-LNPs increases IL-2, IFN-y, TNF-a, and IL- 17 levels, supporting proliferation, survival, and antitumor activity. Concurrent upregulation of perforin, granzymes, granulysin, and Fas ligand enhances both granule-mediated and death-receptor cytotoxic pathways (57). Together, these changes demonstrate that KCNA3-LNPs reshape the cytokine milieu toward an antitumor phenotype.- M -[002061 The efficacy of KCNA3-LNPs is demonstrated by increased intratumoral Granzyme B+CD8+T cell infiltration and reduce tumor burden in a HNSCC mouse model. These effects were achieved through localized peritumoral administration, chosen to maximize LNP delivery to tumor-draining lymph nodes and the TME. While this approach — already used clinically in HNSCC — may limit off-target effects, it could restrict systemic efficacy in metastatic settings (58, 59). Nonetheless, the splenomegaly observed in treated mice suggests some systemic immune modulation. Although human PBMC engraftment in NSG mice can eventually lead to graft-versus-host disease (GvIID) (60), the increased spleen size in KCNA3-LNP-treated mice is consistent with expansion of functional human effector T cells rather than GvHD, as clinical signs of disease progression, including impaired mobility and cachexia, were absent. No spleen enlargement was observed in control mice. Splenic enlargement in KCNA3-LNP-treated mice correlated with higher intratumoral CD8+density and Granzyme B expression, indicating systemic T cell priming that enhances local tumor infiltration. Future work should optimize systemic efficacy, biodistribution, and target engagement, and explore combination with anti-PD1 or CAR-T therapies. Broad profiling of the TME and long-term safety studies will be critical for clinical translation.

[0207] In conclusion, the clinical success of mRNA-LNP technology in COVID-19 vaccines provides a strong foundation for KCNA3-LNP translation (26). Modular, scalable LNP platforms allow rapid adaptation to different cargos and targets. Selective Kvl.3 augmentation represents a form of in vivo T cell engineering that enhances endogenous effector machinery rather than introducing synthetic receptors, potentially overcoming immunosuppression in solid tumors. This approach may extend to other malignancies with immunosuppressive TMEs, such as ccRCC, where high KCNA3 expression correlates with improved survival. Overall, these proof-of-concept studies demonstrated specificity, efficacy, and safety of KCNA3-LNPs and support further development toward clinical trials to improve patient outcomes in solid tumors.REFERENCES

[0208] 1. Feske S, Skolnik EY, Prakriya M: Ion channels and transporters in lymphocyte function and immunity. Nature reviews Immunology 2012, 12:532-47.

[0209] 2. Newton HS, Gawali VS, Chimotc AA, Lehn MA, Palackdharry SM, Hinrichs BH, Jandarov R, Hildeman D, Janssen EM, Wise-Draper TM, Conforti L: PD1 blockade enhances K(+) channel activity, Ca(2+) signaling, and migratory ability in cytotoxic T lymphocytes of patients with head and neck cancer. Journal for immunotherapy of cancer 2020, 8:e000844.[002101 3. Chimote AA, Hajdu P, Sfyris AM, Gleich BN, Wise-Draper T, Casper KA, Conforti L: Kvl.3 Channels Mark Functionally Competent CD8+Tumor- Infiltrating Lymphocytes in Head and Neck Cancer. Cancer Re?earch 2017, 77:53-61.

[0211] 4. Eil R, Vodnala SK, Clever D. Klebanoff CA, Sukumar M, Pan JH, Palmer DC, Gros A, Yamamoto TN, Patel SJ, Guittard GC, Yu Z, Carbonaro V, Okkenhaug K, Schrump DS, Linehan WM, Roychoudhuri R, Restifo NP: Ionic immune suppression within the tumor microenvironment limits T cell effector function. Nature 2016, 537:539-43.

[0212] 5. Hou X, Zaks T, Langer R, Dong Y: Lipid nanoparticles for mRNA delivery. Nature Reviews Materials 2021, 6:1078-94.

[0213] 6. Fadool DA, Tucker K, Perkins R, Fasciani G, Thompson RN, Parsons AD, Overton JM, Koni PA, Flavell RA, Kaczmarek LK: Kvl.3 channel gene-targeted deletion produces "Super-Smeller Mice" with altered glomeruli, interacting scaffolding proteins, and biophysics. Neuron 2004, 41:389 - 404.

[0214] 7. McCloskey C, Jones S, Amisten S, Snowden RT, Kaczmarek LK, Erlinge D, Goodall AH, Forsythe ID, Mahaut-Smith MP: Kvl.3 is the exclusive voltage-gated K+ channel of platelets and megakaryocytes: roles in membrane potential, Ca2+ signalling and platelet count. The Journal of physiology 2010, 588:1399-406.

[0215] 8. Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chavez A, Keegan N, Khamashta MA, Lambotte O, Mariette X, Prat A, Suarez-Almazor ME: Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers 2020, 6:38.

[0216] 9. Khodoun M, Chimote AA, Ilyas FZ, Duncan HJ, Moncneffe H, Kant KS, Conforti L: Targeted knockdown of Kvl.3 channels in T lymphocytes corrects the disease manifestations associated with systemic lupus erythematosus. Science Advances 2020, 6:eabdl471.

[0217] 10. Nicolaou SA, Szigligeti P, Neumeier L, Fee SM, Duncan HJ, Kant SK, Mongey AB, Filipovich AH, Conforti L: Altered Dynamics of Kvl.3 Channel Compartmentalization in the Immunological Synapse in Systemic Lupus Erythematosus. J Immunol 2007, 179:346-56.

[0218] 11. Rurik JG, Tombacz I, Yadegari A, Fernandez POM, Shewale SV, Li L, Kimura T, Soliman OY, Papp TE, Tam YK, Mui BL, Albelda SM, Pure E, June CH, Aghajanian H, Weissman D, Parhiz H, Epstein JA: CAR T cells produced in vivo to treat cardiac injury.Science 2022, 375:91-6.

[0219] 12. Hajdu P, Chimote AA, Thompson TH, Koo Y, Yun Y, Conforti L: Functionalized liposomes loaded with siRNAs targeting ion channels in effector memory T cells as a potential therapy for autoimmunity. Biomaterials 2013, 34:10249-57.[002201 13. L. Q. M. Chow, Head and Neck Cancer. New England Journal of Medicine 382, 60-72 (2020).

[0221] 14. M. G. McCusker, D. Orkoulas-Razis, R. Mehra, Potential of Pembrolizumab in Metastatic or Recurrent Head and Neck Cancer: Evidence to Date. Onco Targets Ther 13, 3047-3059 (2020).

[0222] 15. E. E. W. Cohen, R. B. Bell, C. B. Bifulco, B. Burtness, M. L. Gillison, K. J. Harrington, Q. T. Le, N. Y. Lee, R. Leidner, R. L. Lewis, L. Licitra, H. Mehanna, L. K. Mell, A. Raben, A. G. Sikora, R. Uppaluri, F. Whitworth, D. P. Zandberg, R. L. Ferris, The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC). J Immunother Cancer 7, 184 (2019).

[0223] 16. M. Y. Lee, C. T. Allen, Mechanisms of resistance to T cell-based immunotherapy in head and neck cancer. Head Neck, (2020).

[0224] 17. S. Feske, E. Y. Skolnik, M. Prakriya, Ion channels and transporters in lymphocyte function and immunity. Nat Rev Immunol 12, 532-547 (2012).

[0225] 18. M. D. Cahalan, K. G. Chandy, The functional network of ion channels in T lymphocytes. Immunol Rev 231, 59-87 (2009).

[0226] 19. Z. Kuras, Y. IE Yun, A. A. Chimote, L. Neumeier, L. Conforti, KCa3.1 and TRPM7 Channels at the Uropod Regulate Migration of Activated Human T Cells. PLoS One 7, e43859 (2012).

[0227] 20. J. H. Sim, K. S. Kim, H. Park, K.-J. Kim, H. Lin, T.-J. Kim, H. M. Shin, G. Kim, D.-S. Lee, C.-W. Park, D. H. Lee, I. Kang, S. J. Kim, C.-H. Cho, J. Doh, H.-R. Kim, Differentially Expressed Potassium Channels Are Associated with Lunction of Human Effector Memory CD8+ T Cells. Frontiers in Immunology 8, (2017).

[0228] 21. S. M. Duffy, G. Cruse, S. L. Cockerill, C. E. Brightling, P. Bradding, Engagement of the EP2 prostanoid receptor closes the K+ channel KCa3.1 in human lung mast cells and attenuates their migration. Eur J Immunol 38, 2548-2556 (2008).

[0229] 22. A. A. Chimote, P. Hajdu, V. Kucher, N. Boiko, Z. Kuras, O. Szilagyi, Y. H. Yun, L. Conforti, Selective inhibition of KCa3.1 channels mediates adenosine regulation of the motility of human T cells. J Immunol 191, 6273-6280 (2013).

[0230] 23. A. A. Chimote, Z. Kuras, L. Conforti, Disruption of kvl.3 channel forward vesicular trafficking by hypoxia in human T lymphocytes. J Biol Chem 287, 2055-2067 (2012).

[0231] 24. H. S. Newton, V. S. Gawali, A. A. Chimote, M. A. Lehn, S. M. Palackdharry, B. H. Hinrichs, R. Jandarov, D. Hildeman, E. M. Janssen, T. M. Wise-Draper, L. Conforti, PD1 blockade enhances K(+) channel activity, Ca(2+) signaling, and migratory ability in cytotoxic Tlymphocytes of patients with head and neck cancer. Journal for immunotherapy of cancer 8, e000844 (2020).

[0232] 25. R. Eil, S. K. Vodnala, D. Clever, C. A. Klebanoff, M. Sukumar, J. H. Pan, D. C. Palmer, A. Gros, T. N. Yamamoto, S. J. Patel, G. C. Guittard, Z. Yu, V. Carbonaro, K.Okkenhaug, D. S. Schrump, W. M. Linehan, R. Roychoudhuri, N. P. Restifo, Ionic immune suppression within the tumor microenvironment limits T cell effector function. Nature 537, 539-543 (2016).

[0233] 26. X. IIou, T. Zaks, R. Langer, Y. Dong, Lipid nanoparticles for mRNA delivery. Nature Reviews Materials 6, 1078-1094 (2021).

[0234] 27. D. A. Fadool, K. Tucker, R. Perkins, G. Fasciani, R. N. Thompson, A. D. Parsons, J. M. Overton, P. A. Koni, R. A. Flavell, L. K. Kaczmarek, Kvl.3 channel gene-targeted deletion produces "Super-Smeller Mice" with altered glomeruli, interacting scaffolding proteins, and biophysics. Neuron 41, 389 - 404 (2004).

[0235] 28. C. McCloskey, S. Jones, S. Amisten, R. T. Snowden, L. K. Kaczmarek, D.Erlinge, A. H. Goodall, I. D. Forsythe, M. P. Mahaut-Smith, Kvl.3 is the exclusive voltage-gated K+ channel of platelets and megakaryocytes: roles in membrane potential, Ca2+ signalling and platelet count. J Physiol 588, 1399-1406 (2010).

[0236] 29. M. T. Perez-Garcia, P. Cidad, J. R. Lopez-Lopez, The secret life of ion channels: Kvl.3 potassium channels and proliferation. Am J Physiol Cell Physiol 314, C27-c42 (2018).

[0237] 30. M. Ramos-Casals, J. R. Brahmer, M. K. Callahan, A. Flores-Chavez, N. Keegan, M. A. Khamashta, O. Lambotte, X. Mariette, A. Prat, M. E. Suarez-Almazor, Immune-related adverse events of checkpoint inhibitors. Nature Reviews Disease Primers 6, 38 (2020).

[0238] 31. P. Hajdu, A. A. Chimote, T. H. Thompson, Y. Koo, Y. Yun, L. Conforti, Functionalized liposomes loaded with siRNAs targeting ion channels in effector memory T cells as a potential therapy for autoimmunity. Biomaterials 34, 10249-10257 (2013).

[0239] 32. J. G. Rurik, I. Tombacz, A. Yadegari, P. O. M. Fernandez, S. V. Shewale, L. Li, T. Kimura, O. Y. Soliman, T. E. Papp, Y. K. Tam, B. L. Mui, S. M. Albelda, E. Pure, C. H. June, H. Aghajanian, D. Weissman, H. Parhiz, J. A. Epstein, CAR T cells produced in vivo to treat cardiac injury. Science 375, 91-96 (2022).

[0240] 33. J. Dong, K. Zhang, J. Hong, J. Ye, L. Wang, Q. Ke, Y. Ye, K. Jin, Y. Chen, J. Wu, The multiple functions of CD5 in diseases related to immune disorders. Annals of Medicine 57, 2519682 (2025).

[0241] 34. G. Soldevila, C. Raman, F. Lozano, The immunomodulatory properties of the CD5 lymphocyte receptor in health and disease. Current Opinion in Immunology 23, 310-318 (2011).[00242| 35. H. S. Newton, A. A. Chimote, M. J. Arnold, T. M. Wise-Draper, L. Conforti, Targeted knockdown of the adenosine A2A receptor by lipid NPs rescues the chemotaxis of head and neck cancer memory T cells. Molecular Therapy - Methods & Clinical Development 21, 133-143 (2021).

[0243] 36. F. Sallusto, D. Lenig, R. Forster, M. Lipp, A. Lanzavecchia, Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature 401, 708-712. (1999).

[0244] 37. M. D. Cahalan, K. G. Chandy, T. E. DeCoursey, S. Gupta, A voltage-gated potassium channel in human T lymphocytes. J Physiol 358, 197-237 (1985).

[0245] 38. M. Chirra, H. S. Newton, V. S. Gawali, T. M. Wise-Draper, A. A. Chimote, L. Conforti, How the Potassium Channel Response of T Lymphocytes to the Tumor Microenvironment Shapes Antitumor Immunity. Cancers (Basel) 14, (2022).

[0246] 39. A. A. Chimote, P. Hajdu, A. M. Sfyris, B. N. Gleich, T. Wise-Draper, K. A. Casper, L. Conforti, Kvl.3 Channels Mark Functionally Competent CD8+ Tumor- Infiltrating Lymphocytes in Head and Neck Cancer. Cancer Res 77, 53-61 (2017).

[0247] 40. R. K. Rader, L. E. Kahn, G. D. Anderson, C. L. Martin, K. S. Chinn, S. A.Gregory, T cell activation is regulated by voltage-dependent and calcium-activated potassium channels. The Journal of Immunology 156, 1425-1430 (1996).

[0248] 41. A. Teisseyre, A. Palko-Labuz, K. Sroda-Pomianek, K. Michalak, Voltage-Gated Potassium Channel Kvl.3 as a Target in Therapy of Cancer. Front Oncol 9, 933 (2019).

[0249] 42. I. Szabo, J. Bock, H. Grassme, M. Soddemann, B. Wilker, F. Lang, M. Zoratti, E. Gulbins, Mitochondrial potassium channel Kvl.3 mediates Bax-induced apoptosis in lymphocytes. Proc Natl Acad Sci U S A 105, 14861-14866 (2008).

[0250] 43. L. Leanza, M. Romio, K. A. Becker, M. Azzolini, L. Trentin, A. Managb, E. Venturini, A. Zaccagnino, A. Mattarei, L. Carraretto, A. Urbani, S. Kadow, L. Biasutto, V. Martini, F. Severin, R. Peruzzo, V. Trimarco, J.-H. Egberts, C. Hauser, A. Visentin, G.Semenzato, H. Kalthoff, M. Zoratti, E. Gulbins, C. Paradisi, I. Szabo, Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo. Cancer Cell 31, 516-531.e510 (2017).

[0251] 44. A. B. Mackenzie, H. Chirakkal, R. A. North, Kvl.3 potassium channels in human alveolar macrophages. American Journal of Physiology-Lung Cellular and Molecular Physiology 285, L862-L868 (2003).

[0252] 45. E. Rohner, R. Yang, K. S. Foo, A. Goedel, K. R. Chien, Unlocking the promise of mRNA therapeutics. Nature Biotechnology 40, 1586-1600 (2022).[002531 46. Q. Chen, K. G. Huo, S. M. Ji, S. D. Pang, T. Y. Sun, Y. Niu, Z. H. Jiang, P.Zhang, S. X. Han, J. Y. Li, Unleashing the potential of mRNA: Overcoming delivery challenges with nanoparticles. Bioeng Transl Med 10, el0713 (2025).

[0254] 47. M. Khodoun, A. A. Chimote, F. Z. Ilyas, H. J. Duncan, H. Moncrieffe, K. S. Kant, L. Conforti, Targeted knockdown of Kvl.3 channels in T lymphocytes corrects the disease manifestations associated with systemic lupus erythematosus. Science Advances 6, eabdl471.

[0255] 48. D. Peer, E. J. Park, Y. Morishita, C. V. Carman, M. Shimaoka, Systemic leukocyte-directed siRNA delivery revealing cyclin DI as an anti-inflammatory target. Science 319, 627-630 (2008).

[0256] 49. F. Bayati, M. Mohammadi, M. Valadi, S. Jamshidi, A. M. Foma, E. Sharif- Paghaleh, The Therapeutic Potential of Regulatory T Cells: Challenges and Opportunities.Frontiers in Immunology 11, (2021).

[0257] 50. J. B. Chung, J. N. Brudno, D. Borie, J. N. Kochenderfer, Chimeric antigen receptor T cell therapy for autoimmune disease. Nat Rev Immunol 24, 830-845 (2024).

[0258] 51. G. Schett, F. Muller, J. Taubmann, A. Mackensen, W. Wang, R. A. Furie, R. Gold, A. Haghikia, P. A. Merkel, R. Caricchio, M.-A. D'Agostino, F. Locatelli, C. H. June, D. Mougiakakos, Advancements and challenges in CAR T cell therapy in autoimmune diseases. Nature reviews. Rheumatology 20, 531-544 (2024).

[0259] 52. L. Wang, Y. Liang, C. Zhao, P. Ma, S. Zeng, D. Ju, M. Zhao, M. Yu, Y. Shi, Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential. Signal Transduction and Targeted Therapy 10, (2025).

[0260] 53. C. Zhang, H. Xin, W. Zhang, P. J. Yazaki, Z. Zhang, K. Le, W. Li, H. Lee, L. Kwak, S. Forman, R. Jove, H. Yu, CD5 Binds to Interleukin-6 and Induces a Feed-Forward Loop with the Transcription Factor STAT3 in B Cells to Promote Cancer. Immunity 44, 913-923 (2016).

[0261] 54. A. Matas-Cespedes, L. Brown, K. T. Mahbubani, B. Bareham, J. Higgins, M. Curran, L. de Haan, J. M. Lapointe, R. Stebbings, K. Saeb-Parsy, Use of human splenocytes in an innovative humanised mouse model for prediction of immunotherapy-induced cytokine release syndrome. Clin Transl Immunology 9, el 202 (2020).

[0262] 55. M. M. Cogcls, R. Rouas, G. E. Ghancm, P. Martinivc, A. Awada, D. Van Gcstcl, M. Krayem, Humanized Mice as a Valuable Pre-Clinical Model for Cancer Immunotherapy Research. Frontiers in Oncology Volume 11 - 2021, (2021).

[0263] 56. M. D. Roth, A. Harui, Human tumor infiltrating lymphocytes cooperatively regulate prostate tumor growth in a humanized mouse model. J Immunother Cancer 3, 12 (2015).[00264| 57. K. Tuomela, A. R. Ambrose, D. M. Davis, Escaping Death: How Cancer Cells and Infected Cells Resist Cell-Mediated Cytotoxicity. Frontiers in Immunology Volume 13 -2022, (2022).

[0265] 58. P. Jimenez-Labaig, A. Rullan, I. Brana, A. Hernando-Calvo, V. Moreno, B. Doger, G. Bitar, D. Ap Dafydd, A. Melcher, K. J. Harrington, Intratumoral therapies in head and neck squamous cell carcinoma: A systematic review and future perspectives. Cancer Treatment Reviews 127, (2024).

[0266] 59. N. I. Hussein, A. II. Molina, G. M. Sunga, M. Amit, Y. L. Lei, X. Zhao, J. D. Hartgerink, A. G. Sikora, S. Young, Localized intratumoral delivery of immunomodulators for oral cancer and oral potentially malignant disorders. Oral Oncol 158, 106986 (2024).

[0267] 60. N. Ali, B. Flutter, R. Sanchez Rodriguez, E. Sharif-Paghaleh, L. D. Barber, G. Lombardi, F. O. Nestle, Xenogeneic Graft- versus-Host-Disease in NOD-scid IL-2Rynull Mice Display a T-Effector Memory Phenotype. PLoS One 7, e44219 (2012).

[0268] 61. J. Anaya, B. Reon, W. M. Chen, S. Bekiranov, A. Dutta, A pan-cancer analysis of prognostic genes. Peer.13, el499 (2015).

[0269] 62. A. A. Chimote, M. A. Lehn, J. Bhati, A. E. Mascia, M. Sertorio, M. A. Lamba, D. lonascu, A. L. Tang, S. M. Langevin, M. V. Khodoun, T. M. Wise-Draper, L. Conforti, Proton Treatment Suppresses Exosome Production in Head and Neck Squamous Cell Carcinoma.Cancers (Basel) 16, (2024).

[0270] 63. M. Sheth, M. Sharma, M. Lehn, H. Reza, T. Takebe, V. Takiar, T. Wise-Draper, L. Esfandiari, Three-dimensional matrix stiffness modulates mechanosensitive and phenotypic alterations in oral squamous cell carcinoma spheroids. APL Bioengineering 8, 036106 (2024).

[0271] 64. A. O. Alshwimi, A. A. Chimote, M. V. Khodoun, L. Weatherford, B. H. Hinrichs, H. Wulff, S. N. Waggoner, T. M. Wise-Draper, L. Conforti, KCa3.1 channels regulate the tumor infiltration of functionally competent NK cells in head and neck cancer. Scientific Reports 15, 36360 (2025).

[0272] Although not described in detail herein, other steps which are readily interpreted from or incorporated along with the disclosed embodiments shall be included as part of the invention. The embodiments that have been described herein provide specific examples to portray inventive elements, but will not necessarily cover all possible embodiments commonly known to those skilled in the art. Purifier, it should be understood that each feature described herein can be combined with any one or more other features described herein unless otherwise indicated. Thus, for example, any targeting moiety may be combined with any lipid formulation, any mRNA format, any route of administration, any tumor indication, and any combination therapydescribed herein, unless a particular combination is expressly excluded or technically incompatible.

Claims

WHAT IS CLAIMED IS:

1. A composition comprising:a lipid nanoparticle;a messenger RNA comprising a nucleotide sequence encoding a polypeptide of a potassium channel: anda targeting moiety disposed on a surface of the lipid nanoparticle, wherein the targeting moiety is configured to bind a surface marker of an immune cell;wherein the composition is configured to deliver the messenger RNA to the immune cell and increase expression or activity of the polypeptide in the immune cell.

2. The composition of claim 1, wherein the immune cell is a T cell.

3. The composition of claim 1, wherein the potassium channel is chosen from Kvl.3 and KCa3.1.

4. The composition of claim 3, wherein the potassium channel is Kvl.3 and the nucleotide sequence encodes the KCNA3 gene.

5. The composition of claim 3, wherein the potassium channel is Kca3.1 and the nucleotide sequence encodes the KCNN4 gene.

6. The composition of claim 1, wherein the targeting moiety comprises an antibody or antigen-binding fragment thereof.

7. The composition of claim 1, wherein the T-cell surface marker comprises CD5.

8. The composition of claim 7, wherein the targeting moiety comprises an anti-CD5 antibody or antigen-binding fragment thereof.

9. The composition of claim 1, wherein the messenger RNA further comprises a nucleotide sequence encoding a reporter polypeptide.

10. The composition of claim 9, wherein the reporter polypeptide comprises EGFP.

11. 1'he composition of claim 9, wherein the messenger RNA further comprises a nucleotide sequence encoding a self-cleaving peptide.

12. The composition of claim 11, wherein the nucleotide sequence encoding a self-cleaving peptide comprises a P2A sequence.

13. The composition of claim 1, wherein the lipid nanoparticle comprises:a cationic or ionizable lipid;a phospholipid;a sterol; anda PEG-containing lipid.

14. The composition of claim 10, wherein the lipid nanoparticle comprises DOTAP, phosphatidylcholine, cholesterol, and PE-PEG-biotin.

15. The composition of claim 11, wherein the lipid nanoparticle comprises said components at an approximately 5 :2: 1 : 1 molar ratio of cationic or ionizable lipid to phospholipid, to sterol, to PEG-containing lipid.

16. The composition of claim 1, wherein the lipid nanoparticle has an average particle diameter of about 105 nm to about 120 nm.

17. The composition of claim 1, wherein the messenger RNA further comprises a poly(A) tail.

18. The composition of claim 1, wherein the composition is configured such that expression of the polypeptide of a potassium channel in the immune cell is transient and non-integrating.

19. The composition of claim 1, wherein delivery of the messenger RNA increases one or more of Kvl.3 protein abundance, Kvl.3 channel activity, KCa3.1 protein abundance, KCa3.1 channel activity, calcium influx, cytokine secretion, cytotoxic molecule release, and tumor infiltration by cytotoxic T cells.

20. The composition of claim 18, wherein the cytokine secretion comprises increased secretion of one or more of IL-2, IL- 17, TNF-a, and IFN-y.

21. The composition of claim 18, wherein the cytotoxic molecule release comprises increased release of one or more of Granzyme A, Granzyme B, perforin, granulysin, and Fas ligand.

22. The composition of claim 1, wherein the composition is formulated for local administration to a tumor site or a peritumoral region.

23. A method of increasing antitumor activity of an immune cell in a subject, the method comprising administering to the subject an effective amount of the composition of claim 1, thereby delivering the messenger RNA to an immune cell in vivo and increasing expression or activity of the polypeptide in the immune cell.

24. The method of claim 23, wherein the subject has cancer.

25. The method of claim 24, wherein the cancer is a solid tumor.

26. The method of claim 25, wherein the cancer comprises head and neck squamous cell carcinoma.

27. The method of claim 23, wherein the administration increases one or more of calcium influx, cytokine secretion, cytotoxic molecule release, intratumoral CD8+ T-cell abundance, and Granzyme B-positive CD8+ T cells.

28. The method of claim 23, wherein the administration reduces tumor burden.

29. The method of claim 23, wherein the composition is administered locally at, within, or adjacent to a tumor site.

30. The method of claim 29, wherein the composition is administered peritumorally.

31. The method of claim 23, wherein the method further comprises administering an immune checkpoint inhibitor.

32. The method of claim 31 , wherein the immune checkpoint inhibitor comprises a PD- 1 inhibitor or a PD-L1 inhibitor.

33. The method of claim 31, wherein the immune checkpoint inhibitor comprises an anti-PD1 antibody.